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SUMMARY 1 
 
1 SUMMARY 
Mast cell activation in allergic and inflammatory disease causes increased vascular 
permeability and edema. This thesis identifies a paracrine mechanism, by which 
heparin released from intracellular granules, is involved in mast cell-evoked alteration 
of endothelial barrier function in vivo.  
Negatively charged heparin initiated factor XII-driven contact activation. Activated 
factor XII triggered the formation of the inflammatory mediator bradykinin in plasma. 
Congenital deficiency and pharmacological targeting of factor XII and kinin B2 receptor 
provided protection from mast cell-heparin-induced leukocyte-endothelial adhesion and 
hypotension in rats and mice. Intravital laser scanning microscopy and tracer 
measurements showed that heparin increased leakage with fluid extravasation in skin 
microvessels in mice. Deficiency in factor XII or kinin B2 receptor conferred resistance 
to heparin-induced skin edema and largely protected mice from endothelial barrier 
dysfunction, caused by allergen-induced mast cell activation and anaphylactic 
reactions. In contrast, heparin and mast cell activation caused excessive edema 
formation in mice, deficient in the major inhibitor of factor XII, C1 esterase inhibitor. 
Hereditary angioedema patients, lacking C1 esterase inhibitor, suffered from allergen-
induced edema. The data indicate that mast cell-heparin-initiated bradykinin formation 
plays a fundamental role in defective barrier function of pathological mast cell-mediated 
inflammation, hypotension and edema formation. 
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2 ZUSAMMENFASSUNG 
Aktivierte Mastzellen sind bei Allergien und Entzündungskrankheiten an der 
Ödembildung beteiligt. Diese Arbeit zeigt, wie von aktivierten Mastzellen freigesetztes 
Heparin die Gefäßpermeabilität erhöht. Mastzell-Heparin aktiviert im Plasma den 
Blutgerinnungsfaktor XII. Aktiver Faktor XII startet die Bildung des 
Entzündungsmediators Bradykinin durch Plasmakallikrein-vermittelte Spaltung von 
hochmolekularem Kininogen. Bradykinin führt zur Ödembildung und Vasodilatation. Bei 
Ratten und Mäusen blockieren Faktor XII- oder Kinin B2 Rezeptor-Inhibitoren die 
Heparin-induzierte und Bradykinin-vermittelte Leukozyten-Endothel Adhäsion und den 
arteriellen Blutdruckabfall. Um den Heparin-vermittelten Flüssigkeitsaustritt aus 
Mikrogefäßen in der Haut von Mäusen zu analysieren, wurde eine intravitale konfokale 
Mikroskopietechnik etabliert. Genetische Inaktivierung oder pharmakologische 
Blockierung von Faktor XII oder Kinin B2 Rezeptoren hemmen den Heparin-
vermittelten Flüssigkeitsaustritt. Sowohl in systemischen als auch in cutanen passiven 
Anaphylaxiemodellen waren Faktor XII- und Kinin B2 Rezeptor-defiziente Mäuse vor 
Allergen-induzierten Ödemen und anaphylaktischen Reaktionen geschützt. Im 
Gegensatz dazu führte eine Allergenexposition zu einer überschiessenden 
Ödembildung in C1 Esterase Inhibitor-defizienten Mäusen, bei denen das Gen für den 
wichtigsten Inhibitor von Faktor XII inaktiviert wurde. Bei Hereditären Angioödem-
Patienten, denen funktionaler C1 Esterase Inhibitor fehlt, lösen allergischen 
Reaktionen Ödemattacken aus. 
Zusammenfassend zeigen diese Daten erstmals, dass die durch Heparin gestartet 
Bradykinin-Bildung, eine bedeutende Rolle bei der fehlerhaften Barrierenfunktion der 
pathologischen Mastzell-vermittelten Entzündungen, Blutdruckabfall und Ödembildung 
spielt. 
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3 INTRODUCTION 
3.1 The contact system 
The plasma contact system comprises the serine protease zymogen factor XII (FXII), 
plasma prekallikrein (PPK), the cofactor high molecular weight-kininogen (HK) and C1 
esterase inhibitor (C1INH), the major inhibitor of activated FXII (FXIIa) and plasma 
kallikrein (PK). The name contact system is due to FXII-binding to negatively charged 
surfaces. “Contact” to surfaces induces an autoactivation in FXII resulting in small 
amounts of FXIIa that convert PPK into its active form PK. In a feedback loop PK 
activates additional FXII, which amplifies the initial signal (Cochrane and Revak, 1980, 
Figure 1). 
 
FXIIa triggers four plasma cascade pathways: the intrinsic pathway of coagulation, the 
fibrinolytic, the complement and the kallikrein-kinin system (Margolis, 1958; Ratnoff et 
al., 1961; Kaplan and Austen, 1972; Ghebrehiwet et al., 1981; Muller and Renne, 
2008). The kallikrein-kinin system generates vasoactive proinflammatory kinin 
hormones. The peptide-hormone bradykinin (BK) is released by limited proteolysis from 
its precursor HK by PK action. PK cleaves HK at the C-terminus of the BK sequence, 
leaving the BK sequence attached to the C-terminal end of the HK-heavy chain 
(Nishikawa et al., 1992). Then a second cleavage liberates BK from the HK-heavy 
chain and a two-chain, kinin-free HK is formed. The two-chain from consists of the 
heavy chain (65 kDa) that is disulfide bond linked to the light chain (56 kDa) 
(Thompson et al., 1978). The vasoactive proinflammatory BK is a nonapeptide with the 
amino acid sequence Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9. It binds to the cell 
surface kinin B2 receptor (B2R) with a dissociation constant KD = 1.2 nM (Schremmer-
Figure 1. The plasma contact system. FXII is 
autoactivated to FXIIa that cleaves PPK to form PK. PK 
enhances FXIIa formation in a positive feedback loop. PK 
cleaves HK to liberate BK. 
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Danninger et al., 1995; Yang et al., 1999). B2R belongs to the G protein-coupled 
receptor family, which are characterized by seven transmembrane-spanning helices. 
B2R is predominantly coupled to G proteins of the Gαq and Gαi families (Liao and 
Homcy, 1993; Yang et al., 1999). B2R is constitutively expressed in various cell types, 
such as endothelial cells, vascular smooth muscle cells and cardiomyocytes (Shukla et 
al., 2006). BK binding to B2R increase intracellular calcium levels, that trigger 
activation of cyclic adenosine monophosphate/cyclic guanosine monophosphate 
(cAMP/cGMP)-dependent protein kinases (PKA, PKG) and protein kinase C (PKC) 
(Newton, 1995; Francis et al., 2010). A common target for all three protein kinases is 
the actin-binding vasodilator-stimulated phosphoprotein (VASP) (Butt et al., 1994; 
Chitaley et al., 2004), which is localized to cell-cell contacts and involved in actin 
dynamics (Reinhard et al., 1992). The actin cytoskeleton is linked to interendothelial 
junctions, which connect endothelial cells to each other (Drenckhahn and Franz, 1986; 
Rimm et al., 1995). Actin assembly and disassembly regulates the integrity of these 
cell-cell adhesions and therefore the endothelial cell permeability (Stevenson and 
Begg, 1994; Anderson and Van Itallie, 1995). One type of interendothelial junctions is 
tight junctions. A tight junction-associated scaffold protein is αII-spectrin, which binds to 
VASP, linking the plasma membrane with the actin cytoskeleton. Complexes of VASP 
with αII-spectrin stabilize cell-cell contacts (Benz et al., 2008). VASP phosphorylation 
by PKA/PKG or PKC inhibits the interaction to spectrin leading to destabilization of cell-
cell contacts, disassembly of tight junction, formation of cellular gaps, followed by 
increase in vascular permeability (Comerford et al., 2002; Benz et al., 2008). Another 
BK-triggered signaling pathway mediates the rearrangement of actin filaments into 
stress fibers, resulting in cellular contraction, which also induces tight junction 
disassembly and increased permeability (Ma and Xue, 2010, Figure 2). 
INTRODUCTION 5 
 
 
 
 
 
After BK binding to B2R the receptor is internalized (Pizard et al., 1999), and continues 
signaling. Non-receptor bound BK has a half-life of <1 min in plasma (Frick et al., 2006) 
and is degraded by endo- and exopeptidases, such aminopeptidase P, 
carboxypeptidase M and N and neutral endopeptidase (Skidgel, 1992). The major BK-
degrading enzyme is the angiotensin-converting enzyme (ACE), also known as 
kininase II. It chips off the C-terminal dipeptide (Phe8-Arg9) from BK and is therefore 
classified as an exopeptidase (peptidyl dipeptidase). The resulting BK-(1-7) does not 
bind to B2R (Kokkonen et al., 2000). 
 
 
3.2 Coagulation factor XII 
FXII is a glycoprotein of 80 kDa that is primarily produced by hepatocytes. It circulates 
in plasma as a single chain zymogen with a concentration of 30-35 µg/mL (0.37 µM). 
The zymogen consists of 596 amino acids (Fujikawa and McMullen, 1983; McMullen 
and Fujikawa, 1985). FXII is composed of a fibronectin domain type II (at the N-
terminus), an epidermal-growth-factor-like domain, a fibronectin domain type I, a 
second epidermal-growth-factor-like domain, a kringle domain, a proline-rich region 
and the catalytic domain (McMullen and Fujikawa, 1985). The catalytic domain with the 
Figure 2. Bradykinin signaling. Bradykinin binding to its B2 receptor activates protein kinase A, C, and 
G, which phosphorylate VASP. Bradykinin induces stress fiber formation and cellular contraction leading 
to tight junction disassembly and increase of vascular permeability. 
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active site of FXIIa contains the catalytic triad Asp442, His393, and Ser554 (Schloesser et 
al., 1997). 
FXII is activated to FXIIa (α-FXIIa) via autoactivation or proteolytic cleavage by plasma 
proteinases including PK and plasmin. The peptide-bond connecting Arg353-Val354 is 
cleaved and a two-chain molecule is generated. The heavy chain (353 amino acids, 50 
kDa) and the light chain (243 amino acids, 30 kDa) are hold together by a single 
disulfide bond between Cys340-Cys346. FXII-autoactivation takes place upon contact to 
negatively charged surfaces resulting in conformational changes (Samuel et al., 1992). 
The binding of zinc ions to FXIIa results in an increased susceptibility to autoactivation 
and stabilizes certain conformations in the activation reaction (Bernardo et al., 1993). 
FXIIa cleavages at the peptide bonds Arg334-Asn335 and Arg343-Leu344 by PK separate 
the heavy from the light chain. The resulting activated FXII-fragment (β-FXIIa, FXIIf, 
28 kDa) consists of the light chain and nine amino acids of the C-terminal part of the 
FXII heavy chain (Dunn and Kaplan, 1982; Tankersley and Finlayson, 1984). Although 
retaining its proteolytic activity towards PPK, β-FXIIa is unable to bind to negatively 
charged surfaces and therefore is not able to convert factor XI (FXI) to active FXI 
(FXIa) and fails to promote blood clotting (Dunn et al., 1982).  
The major inhibitor of α- and β-FXIIa, and PK in plasma is C1INH (de Agostini et al., 
1984; Pixley et al., 1985b). C1INH is a suicide serine protease inhibitor (serpin) that 
inhibits proteases from the coagulation pathway and also the complement protease 
C1s and C1r. C1INH is a highly glycosylated protein of 478 amino acids with a 
molecular weight of 94 kDa (Zuraw and Curd, 1986). C1INH consists of an N-terminal 
domain of 113 amino acids, and a serpin domain of 365 amino acids, both are 
connected via two disulfide bonds (Bos et al., 2002). The serpin contains a reactive, 
flexible peptide loop for interaction with target proteases. Essential residues of this loop 
are called P1–P1´ residues, which are located next to each other (Bos et al., 2002). 
Cleavage of this specific peptide-bond in the reactive center of the serpin (exon 8 
codes for the reactive center, (Nielsen et al., 1998) triggers a molecule-rearrangement 
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and results in the formation of a covalent peptide-bond between the P1 residue of the 
C1INH and the Ser554 from the active site of the protease (Davis, 2008). The formed 
peptide-bond between C1INH and FXIIa inactivates the catalytic triad of the protease 
and the protease is inhibited. Other physiological inhibitors of FXIIa comprise 
antithrombin and α2-macroglobulin (Pixley et al., 1985a; Berrettini et al., 1989). 
 
 
3.3 Activators of kallikrein-kinin system 
Formation of BK can be initiated by several FXII activators. A common feature of all 
known activators is that they are negatively charged macromolecules, which can be 
divided into two groups: artificial substances such as glass, kaolin and ellagic acid and 
natural occurring substances including nucleotides, sulfates, micelles and 
glycosaminoglycans (Table 1). 
 
Artificial activators Natural activators 
Glass DNA/RNA 
Kaolin Sulfatides/micelles 
Celite and cilica Urea crystal 
Ellagic acid Collagens 
Polyethylene Glycosaminoglycans 
Dextran sulfate Endotoxin 
 Polyphosphates 
 Misfolded proteins 
 
Glycosaminoglycans such as squid chondroitin sulfate E and heparin from rat 
peritoneal mast cells activate the contact system in vitro (Hojima et al., 1984). In human 
plasma ex vivo experiment heparin from a murine mastocytoma-derived mast cell line 
accelerated the reciprocal activation of FXIIa and PK and the autoactivation of FXII 
(Brunnee et al., 1997). Recent studies identified new FXII activators: misfolded protein-
aggregates activate FXII leading to activation of the kallikrein-kinin system without 
inducing the intrinsic pathway of coagulation (Maas et al., 2008). In contrast, platelet-
derived polyphosphates activate the contact system resulting in activation of both, the 
intrinsic pathway of coagulation and the kallikrein-kinin system (Muller et al., 2009). The 
Table 1. Contact system activators. (Maas et al., 2011)
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kallikrein-kinin system can be activated by bacteria. The components of the contact 
system assembly on structures of the bacterial surface (negatively charged 
lipopolysaccharides and lipid A of Escherichia coli (E. coli); peptidoglycan and teichoic 
acid of Staphylococcus aureus; fimbriae of Salmonella typhimurium and M protein of 
Group A streptococci) (Kalter et al., 1983; Ben Nasr et al., 1996; Persson et al., 2000; 
Mattsson et al., 2001; Frick et al., 2007). On the bacteria surface HK is cleaved by 
bacterial secreted kininogen-degrading proteinases to release BK (streptococcal 
proteinase is secreted by Group A streptococci; Staphylococcus aureus and 
Streptococcus pyogenes secrete a cysteine proteinase (Herwald et al., 1996; Imamura 
et al., 2005; Linder et al., 2010)) . Since it was shown, that PPK can be activated FXII-
independently on endothelial cells (Motta et al., 1998) other substances were 
discovered that activate the kallikrein-kinin system FXII-independently. Intracellular 
chaperon heat shock protein 90 (Joseph et al., 2002), the mitochondrial 
prolylcarboxypeptidase (Shariat-Madar et al., 2004) and extracellular 
carbonicanhydrase (Gao et al., 2007) have the capacity of activating PPK. 
Physiological importance of these activators is currently unknown. 
 
 
3.4 Mast cells 
Mast cells (MC) are derived from multipotent hematopoietic progenitor cells in the bone 
marrow (Kitamura et al., 1981). The cells enter into the blood circulation and 
differentiate within various tissues (Hallgren and Gurish, 2007). Migration and 
differentiation take place under the influence of the local micromilieu, including growth 
factors, integrins, chemokines and adenosine nucleotides (Taub et al., 1995; 
McCloskey et al., 1999). The most important growth factor for MC is stem cell factor, 
the ligand for the c-kit receptor (Li and Krilis, 1999). 
Two major subtypes of human MC can be distinguished dependent on the presence of 
tryptase (T) or tryptase and chymase (TC): MCT and MCTC (Moon et al., 2010). MCT are 
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the prominent MC type in the mucosa of the respiratory and gastrointestinal tract and 
increase with mucosal inflammation. MCTC are localized within connective tissues, such 
as the dermis, submucosa of the gastrointestinal tract, heart, conjunctiva, and 
perivascular tissues (Metcalfe, 2008). In rodents connective tissue MC (MCCT) and 
mucosal MC (MCM) are described. MCCT are predominantly found in the skin and 
peritoneal cavity. Their granules contain the polysaccharide heparin, histamine and 
carboxypeptidase A. In contrast, MCM are found predominantly in the mucosal layer of 
the gut and lungs. Their granules contain chondroitin sulfate as the major 
polysaccharide compound and relatively less histamine and carboxypeptidase A (Heib 
et al., 2008; Rao and Brown, 2008). In human and mice the different milieu of cytokines 
and the tissue-specific expression of stem cell factor are responsible for the 
heterogeneity of differentiation and distribution of MC in specific tissues. 
MC can be activated by different mechanisms: via toll-like receptors, which are 
important for direct pathogen recognition; via complement products such as C3a and 
C5a (Nilsson et al., 1996; Marshall, 2004; Dawicki and Marshall, 2007); and via IgG-
antibody, which binds to its high-affinity receptor FcγRI. The best characterized 
pathway for MC activation is the antigen-dependent aggregation of the high-affinity 
receptor for IgE (FcεRI). FcεRI contains three immunoreceptor tyrosine–based 
activation motifs (ITAM), which are phosphorylated after receptor aggregation. The 
phosphorylations trigger a number of downstream signaling events, such as activation 
of phospholipase C-γ, increase of intracellular calcium and PKC activation, activation of 
transcription factors and metabolism of arachidonic acid via phospholipase A2. 
Phosphatidylinositol kinase (PI3K) is activated, that regulates the formation of lipid 
mediators, such as spingosine 1-phosphate, that in turn regulates MC degranulation. 
Soluble N-ethylmaleimide attachment protein receptors complexes are formed, that 
promote membrane fusion and thereby mediator secretion (Blank et al., 2002; 
Kalesnikoff and Galli, 2008; Stone et al., 2010). MC produce an array of vasoactive 
mediators and proinflammatory substances that are either preformed granule-
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associated mediators, newly generated lipid mediators or belong to a wide variety of 
cytokines and chemokines (Kalesnikoff and Galli, 2008). Preformed mediators include 
histamine (Riley and West, 1953), proteoglycans, serine proteases (tryptase and 
chymase, (Kido et al., 1985), carboxypeptidase A and antimicrobial peptides, which 
play roles in recruitment and activation of T cells, neutrophiles, basophiles and 
eosinophiles. De novo synthesized mediators include lipids, cytokines, and 
chemokines. Lipid mediators are prostaglandins, leukotrienes and platelet-activating 
factor, which contribute to recruitment and activation of monocytes and macrophages 
(Liu et al., 2010; Stone et al., 2010). A well-established concept is that MC mediators, 
particularly the vasoactive amines histamine or serotonin, increase capillary leakage 
and may rapidly produce edema. Histamine receptor antagonists are therapeutically 
used to treat edema formation and allergic reactions associated with aberrant MC 
activity, e.g. in asthmatic disease (Theoharides and Kalogeromitros, 2006). MC 
secretory granules also contain highly sulfated polysaccharides, such as heparin. 
Although heparin is one of the most studied molecules, its physiological function in vivo 
has yet to be determined (Oschatz et al., 2011). 
 
 
3.5 Heparin 
Heparin is a linear, unbranched, highly sulfated polysaccharide consisting of repeating 
disaccharide units of 1-4-linked iduronic acid and glucosamine. It is exclusively stored 
in cytoplasmatic secretory granules of MCTC (Casu, 1985; Rabenstein, 2002). The 
average heparin disaccharide unit contains 2.7 sulfate groups. Therefore heparin has a 
high negatively charge density (Capila and Linhardt, 2002, Figure 3). 
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Heparin is biosynthesized in the Golgi apparatus as heparin proteoglycan (750–1000 
kDa), which consists of a serglycin core protein to which multiple heparin 
polysaccharide chains (600–100 kDa) are covalently attached (Robinson et al., 1978). 
Biosynthesis of polysaccharide chains takes place in three phases: chain initiation, 
polymerization and polymer modification. The first step involves the attachment of a 
linkage-region tetrasaccharide to a serine residue of the core protein (Salmivirta et al., 
1996). Then, the heparin polysaccharide chains are built up by alternating addition of 1-
4 linked iduronic acid or glucosamine units to the tetrasaccharide core. Approximately 
150 disaccharide units are added before the synthesis terminates (Capila and Linhardt, 
2002). During elongation the chain is modified by a series of sequential N-
deacetylase/N-sulfotransferase, epimerase and O-sulfotransferase-catalyzed reactions 
(Lindahl et al., 1972; Jacobsson and Lindahl, 1980; Rosenberg et al., 1997). All 
subsequent modifications are dependent on the N-sulfate groups for substrate 
recognition, which makes the N-deacetylation/N-sulfation step very important. The 
structural variability of the heparin polymer is the result of incomplete modifications by 
the biosynthetic enzymes. Finally the polysaccharide chains are randomly cleaved 
along the chains to fragments of 5-40 kDa. Heparin is stored in cytoplasmatic secretory 
granules of MCTC as non-covalent complexes with histamine, MC proteases and other 
mediators (Rabenstein, 2002). The physiological significance of heparin in MC granula 
for storage of other mediators has been shown by disruption of the N-deacetylase/N-
sulfotransferase gene in mice (Forsberg et al., 1999; Humphries et al., 1999). Targeting 
the modifying enzyme blocked the biosynthesis of “normal” (sulfated) heparin, resulting 
in largely decreased amounts of several MC proteases and histamine. MC-released 
Figure 3. Heparin disaccharide 
unit.  The average heparin 
disaccharide consists of iduronic 
acid and glucosamine and contains 
3 sulfate groups (Rabenstein, 
2002). 
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heparin can interact with a number of biologically important proteins 
(growth/differentiation factors such as fibroblast growth factor-1 and -2, cytokines such 
IL-8, protease inhibitors such as antithromin III (ATIII), enzymes or adhesion molecules 
such as selectin or fibronectin, (Capila and Linhardt, 2002; Sugahara and Kitagawa, 
2002). Thereby heparin plays an essential role in the regulation of various physiological 
processes including inhibition of complement activation (Weiler et al., 1992), inhibition 
of angiogenesis (Hasan et al., 2005) and tumor growth (Borsig et al., 2001).  
Heparin is used as an anticoagulant drug based on its ability to accelerate the rate at 
which ATIII inhibits serine proteases in the blood coagulation cascade. ATIII by itself is 
a relative weak inhibitor. But heparin-ATIII binding via a unique pentasaccharide 
sequence enhances ATIII mediated inhibition of thrombin and activated factor X (FXa) 
(Lindahl et al., 1979; Rosenberg and Lam, 1979). The ATIII-binding pentasaccharide 
sequence is rare and occurs only in one third of the heparin chains. Its most 
distinguishing feature is an unusual 3-O-sulfate group on an internal glucosamine 
residue, which is essential for its high affinity to ATIII (Lindahl et al., 1980; Petitou et al., 
1988; Walenga et al., 1988).  
 
 
3.6 Hereditary angioedema type III 
Patients with hereditary angioedema (HAE) suffer from life-threatening edema, which 
can lead to death. HAE has a prevalence of 1:10.000 to 1:50.000. Affected individuals 
are from all races. HAE is an autosomal dominant disease associated with episodic 
attacks of subcutaneous or submucosal edema that affected extremities, face or larynx 
(Frank et al., 1976; Davis, 2008; Zuraw, 2008). Three different types of HAE exist. HAE 
I and II are caused by mutations in the Serping1 gene coding for the C1INH protein. 
Type I is caused by mutations leading to decreased levels of C1INH (quantitative 
defect). In type II the mutated C1INH protein is secreted in normal concentration but 
has a misfolded formation resulting in reduced enzymatic activity (functional defect). In 
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HAE type I and II, absence of C1INH function leads to excessive BK generation, 
resulting in angioedema. Recently, a new type of HAE (HAE type III) has been 
identified, which clinically does not differ from HAE I or II. The disease exhibits no 
quantitative or functional C1INH abnormalities. Most affected individuals are women 
(Bork et al., 2000; Bork et al., 2006). Swelling attacks are often during pregnancy or 
when receiving oral contraceptives containing oestrogens (Binkley and Davis, 2000; 
Martin et al., 2001; Gupta et al., 2004; Bork et al., 2006; Vitrat-Hincky et al., 2010). 
Genetic analyses revealed two missense mutations at position Thr328 (1032C→A: Thr 
exchange to Lys and 1032C→G: Thr exchange to Arg) in the factor 12 gene of affected 
women from different families as a possible cause of HAE III (Cichon et al., 2006; 
Dewald and Bork, 2006; Picone et al., 2010). Biochemical studies showed that FXII-
Thr328Lys mutation is a gain-of-function mutation, which increases FXII enzymatic 
activity but do not alter FXII plasma levels (Cichon et al., 2006). Enhanced FXII 
enzymatic activity leads to enhanced kinin production. Stimuli triggering the periodic 
episodes of excessive vascular leakage are poorly defined. 
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3.7 Aim of the study 
The biochemistry of the contact system is well characterised, however it is less 
understood how the system is activated in vivo. Heparin is a high negatively charged 
polysaccharide that is exclusively found in MC granules  (Forsberg et al., 1999). It is 
known, that MC-heparin activates the contact system in vitro leading to BK formation 
(Hojima et al., 1984; Brunnee et al., 1997). Heparin is used as an anticoagulant drug. 
In rare cases, adverse reactions including drop in blood pressure and edema in various 
tissues including the skin have been reported after heparin application (MacLaughlin et 
al., 2002). Although heparin is a well studied molecule, it is not known whether heparin 
functions in MC-triggered vascular effects in vivo. 
 
The aim of this study was to analyze MC-heparin for its ability to trigger activation of 
contact system in vivo using vascular leakage and anaphylaxis models in rodents. 
The goals of the presented work can be divided into the following parts: 
I) Characterisation of MC-heparin as a FXII-dependent activator of the contact 
system in vitro  
II) Analysis of MC-heparin-driven BK-mediated vascular leakage and hypotension 
in rodents 
III) Analysis of genetically and pharmacologically targeting of FXII or B2R for MC-
driven effects 
IV) Investigation of allergen-stimulated MC to induce BK-mediated edema in 
genetically altered mice and in hereditary angioedema patients 
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4 MATERIAL AND METHODS 
4.1 Plasma and animals 
4.1.1 Human plasma 
FXI-, FXII-, and PK-deficient human plasma was purchased from George King Bio 
Medical (Overland Park, Kansas, USA). Control citrated plasma was collected from 
healthy volunteers (University Hospital Würzburg, Germany and blood transfusion unit 
of the Karolinska Hospital, Stockholm, Sweden).  
 
4.1.2 Animals 
All procedures and animal studies were approved by local authorities. Wild-type (WT) 
C57BL/6 mice and male Spraque-Dawley rats (8 weeks of age) were purchased from 
Charles River Wiga (Sulzfeld, Germany) (Oschatz et al., 2011). MC deficient B6.Cg-
KitW-sh/HNihrJaeBsmJ mice (KitW-sh/W-sh) were purchased from the Jackson Laboratory 
(Bar Harbor, Maine, USA) (Oschatz et al., 2011). Generation and phenotyping of 
Serping1-/- mice is described under 4.2.9. All used mice strains are listed below (Table 
2). Mice were used between 6-12 weeks of age (Oschatz et al., 2011). 
 
 
Mice strain Name of inactivated 
protein 
Reference 
F12-/- Factor XII (Pauer et al., 2004 ) 
Bdkrb2-/- Kinin B2 Receptor (Borkowski et al., 1995 ) 
KitW-sh/W-sh C-Kit (Yamazaki et al., 1994) 
Serping1-/- C1 esterase inhibitor (Oschatz et al., 2011) 
VASP-/- VASP (Hauser et al., 1999) 
 
 
4.2 Methods 
4.2.1 Sodium dodecyl sulfate-polyacrylamide gelelectrophoresis and Western 
blotting 
Protein/plasma samples were separated by sodium dodecyl sulfate-polyacrylamide 
gelelectrophoresis (SDS-PAGE) using 10% or 12% gels (Table 3).  
Table 2: Genetically altered mice strains.
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 Stacking gel Separating gel 
 10% 12% 
H2O 3.4 mL 4.0 mL 3.3 mL 
30% acrylamide mix (Roth) 0.83 mL 3.3 mL 4.0 mL 
1.5 M Tris (pH 8.8; Roth) - 2.5 mL 2.5 mL 
1.0 M Tris (pH 6.8; Roth) 0.63 mL - - 
10% SDS (Roth) 0.05 mL 0.1 mL 0.1 mL 
10% ammonium persulfate 
(Sigma) 
0.05 mL 0.1 mL 0.1 mL 
N,N,N′,N′-
Tetramethylethylenediamine 
(Roth) 
0.005 mL 0.004 mL 0.004 mL 
Total volume 5 mL 10 mL 10 mL 
 
Plasma samples were diluted in SDS-PAGE sample buffer (50 mM TrisHCl pH 6.8 
(Roth, Karlsruhe, Germany), 100 mM dithiothreitol (Sigma, Steinheim, Germany), 2% 
SDS (Biotium/VWR international, Stockholm, Sweden), 0.1% bromophenol blue 
(Sigma), 10% glycerine (Roth)), heated to 95°C for 5 min and were loaded on the gel. 
As molecular weight marker Page Ruler prestained Protein Ladder (Fermentas, 
St.Leon-Rot, Germany) was used. Electrophoresis started with 80 V and voltage was 
increased to 150 V after samples reached the separation gel border (electrophoresis 
buffer: 25 mM Tris (Roth), 250 mM glycerine pH 8.3, 0.1% (w/v) SDS). Proteins were 
transferred (0.65 mA/ membrane cm2 for 1.5 h at room temperature (RT), transfer 
buffer: 39 mM glycerine, 48 mM Tris base, 0.037% SDS, 20% methanol (Sigma)) to a 
in methanol activated polyvinylidene difluoride membrane (pore size 0.45 µm, Milipore, 
Schwalbach, Germany) using a biometra Power Pack P25 power supply system 
(Göttingen, Germany). The nitrocellulose was stained with Ponceau S (Roth) to verify 
protein presence. The membrane was washed with PBS-Tween (PBS-T; PBS with 
0.05% (v/v) Tween 20, Roth). To reduce unspecific antibody (Ab) binding, membrane 
was blocked with 5% (w/v) milk powder (Roth) in PBS-T for 2 h at RT or overnight at 
4°C. Membrane was incubated with diluted primary Ab in 5% milk powder in PBS-T 
(Table 4) for 2 h at RT, washed twice with PBS-T, and incubated with diluted 
secondary Ab in 5% milk powder in PBS-T (Table 4) for 1 h at RT. Membrane was 
washed twice with PBS-T and proteins were detected with Amersham ECL Western 
Table 3: Solutions for preparing SDS-PAGE gels.
MATERIAL & METHODS 17 
 
Blotting Detection reagents (GE healthcare, Freiburg, Germany), X-ray films from 
Thermo scientific (Rockford, Illinois, USA) and a developer machine (Eastman Kodak 
Company, Rochester, New York, USA) according to the manufacturer’s instructions. 
 
 
Primary 
antibody 
Concentration 
/Dilution 
Secondary 
antibody  
 
Dilution 
Company/ 
Reference 
PK6,  
purified mouse 
mAb to heavy 
chain of PK 
2 µg/mL goat -mouse 
(Jackson Immuno 
Research; 115-
035-003) 
1:2000 (Hock et al., 1990) 
HKL12, 
purified mouse 
mAb to light 
chain of HK 
0.5 µg/mL 
 
goat -mouse 
(Jackson Immuno 
Research; 115-
035-003) 
1:2000 (Renne et al., 2005b) 
I108,  
purified sheep 
pAb to heavy 
chain of HK 
1 µg/mL donkey -sheep 
(Jackson Immuno 
Research; 713-
035-147) 
1:5000  
-HK AS94, 
sheep pAb to 
light and heavy 
chain of HK 
1:500 Serum donkey -sheep 
(Jackson Immuno 
Research; 713-
035-147) 
1:2000  
I107,  
purified sheep 
pAb to light 
chain of HK 
1 µg/mL donkey -sheep 
(Jackson Immuno 
Research; 713-
035-147) 
1:2000 (Renne and Muller-
Esterl, 2001) 
MBK3,  
purified mouse 
mAb to BK 
sequence in HK 
1 µg/mL 
 
donkey -rabbit 
(Jackson Immuno 
Research; 711-
035-1520) 
1:2000 (Haasemann et al., 
1991) 
GAHu/FXI,  
goat pAb to FXI 
 
1:2500 Serum donkey -goat 
(Jackson Immuno 
Research; 705-
035-003) 
1:2000 Nordic Immunological 
Laboratories, Tilburg, 
the Netherlands 
GAHu/FXII,  
goat pAb to FXII 
1:2500 Serum  donkey -goat 
(Jackson Immuno 
Research; 705-
035-003)  
1:2500 Nordic Immunological 
Laboratories, Tilburg, 
the Netherlands 
 
 
-C1INH, 
purified rabbit 
pAb to 23 -36 
amino acid of 
murine C1INH 
2 µg/mL donkey -rabbit 
(Jackson Immuno 
Research; 711-
035-1520) 
1:3000 (Oschatz et al., 2011) 
 
Horseradish peroxidase-conjugated secondary Ab were from Jackson Immuno 
Research (Hamburg, Germany). 
 
Table 4: Antibodies for Western blotting.
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4.2.2 Isolation of heparin from mast cells 
Male rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.; Nembutal, 
Ceva, Paris, France) and 20 mL of sterile ice-cold PBS were injected i.p.. After 1 min 
peritonealexudate was taken. MC were isolated via two centrifugation steps at 400 x g 
for 15 min at RT using a density gradient of 22.5% w/v Metrizamide (Sigma). MC were 
resuspended in PBS, centrifuged and 750 µL RPMI-media (Life Technologies, Lohne, 
Germany) were added. MC concentration was determined by Giemsa (Roth)-stained 
cytospots to 3.5 x 105 cells per mL. MC suspension was halved and incubated with 
compound 48/80 (C48/80; Simga; 4 µg/mL), or medium for 45 min at 37°C in a 5% 
(v/v) CO2 atmosphere. Subsequently, the supernatant was separated by centrifugation 
at 2000 × g for 15 min at 25°C and incubated for 1 h at 37°C with protease inhibitors (1 
mM EDTA (Sigma), 1 mM phenylmethylsulfonylfluorid (Roth), 1 mM leupeptin (Sigma), 
5 mM benzamidine (Roth), 1 mM soybean trypsin inhibitor (Roth) and 10 mg/mL 
Pefabloc (Roth)). All low molecular molecules of the supernatant (<2000 Da) were 
removed by a two-time gel filtration on a Sepharose 4B column (Bio-Rad, Hercules, 
California, USA) and the passage was lyophilized.  
The purity of MC-derived glycosaminoglycans was determined as previously described 
(Katz et al., 1986; Oschatz et al., 2011). Heparinase (from Flavobacterium heparinu) 
and chondroitinase ABC (from Proteus vulgaris) (both from Seikagaku, Tokyo, Japan) 
digests and absorbance measurements at 232 nm indicated that the purified material 
was >95% heparin (Oschatz et al., 2011). The amount of glycosaminoglycans was 
quantified by determining the uronic acid content using the carbazole method (Oschatz 
et al., 2011). Incubation of MC-purified heparin with trypsin, chymotrypsin, elastase, or 
papain (Sigma) had no measurable effect on the filtration behavior on Sepharose 4B 
columns (Bio-Rad) compared with untreated material, indicating that the size of the 
native molecule was not changed and that the glycosaminoglycan was not complexd 
with proteins (Oschatz et al., 2011). 
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4.2.3 Contact activation system assays in vitro 
HK cleavage was initiated in fresh human citrate plasma using MC-derived heparin, 
heparinase treated MC-derived heparin, heparan sulfate (Sigma), dextran sulfate 
(Sigma), sulfated heparin or desulfated heparin. Following incubation for 30 min at 
37°C, the reaction was stopped by addition of SDS-PAGE sample buffer containing 8% 
(m/v) SDS, and 0.25 µL plasma was separated by a 10% polyacrylamide gel and 
analyzed by Western blotting. Ab against BK MBK3 was used to detect uncleaved HK. 
To test the factors, which are involved in HK cleavage and BK liberation, FXI-, FXII-, 
and PK-deficient plasma or normal plasma were incubated with 20 µg/mL MC-derived 
heparin for 30 min at 37°C. Plasma was separated by SDS-PAGE and analyzed by 
Western blotting. To detect FXII, FXI, PK or low molecular weight-kininogen (LK) 
GAHu/FXII, GAHu/FXI, PK6 or I107 Ab were used, respectively.  
BK concentrations were determined by MARKIT-M-Bradykinin ELISA according to the 
manufacturer’s instruction (Dainippon Pharmaceutical, Osaka, Japan) (Oschatz et al., 
2011). 
 
4.2.4 Bradykinin generation on endothelial cell surfaces 
Cultivation of EA.hy926 endothelial cells (Benz et al., 2008) and cell-binding assays 
with [125I]-radiolabeled HK was performed as described previously (Renne et al., 2000; 
Oschatz et al., 2011). BK concentrations were determined by MARKIT-M-Bradykinin 
ELISA. 
 
4.2.5 Coagulation assays 
Adult mice were killed by inhalation of CO2. 800 µL of citrate anticoagulant blood 
(0.36% citrate) were taken by cardial puncture. Blood was centrifuged at 5.000 rpm for 
5-10 min at RT. Supernatant was taken and centrifuged again at 5.000 rpm for 5-
10 min at RT to obtain platelet pure plasma (PPP). To prepare an activated partial 
thromboplastin time (aPTT)-standard curve for unfractionated heparin (Liquemin, 
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Roche, Mannheim, Germany), 0-2 µg/mL of the polysaccharide was added to murine 
PPP. APTT was measured by automated blood coagulation system (BCS XP 1.1, 
Siemens, Eschborn, Germany) with reagents according to the protocols of the 
manufacturer. To determine heparin levels in murine platelet pure plasma after 
systemic anaphylaxis, aPTT was measured and compared to the standard curve. 
Specificity of heparin anticoagulant activity was confirmed by repeated aPTT 
determination after pretreatment with protamine sulfate (Sigma; 1-2 µg/mL) or 0.5 U/mL 
heparinase (Sigma) for 30 minutes at 37 ºC (Oschatz et al., 2011). 
 
4.2.6 Heparin-induced bradykinin generation in rats 
Male rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.; Nembutal, 
Ceva, Paris, France). Catheters were placed into the carotid artery and vena cava, and 
the jugular artery and vein. The rats were placed in a supine position on a heated 
operating pad. Mean systolic arterial blood pressure was measured in the left carotid 
artery using an arterial catheter connected to a Statham pressure transducer (type P 
23 I; Gould, Oxnard, California, USA) and recorder (LS 64; Linseis, Selb, Germany). A 
bolus of 10 mg/kg bw heparin was applied into the aorta or femoral artery to trigger 
hypotension or inflammation, respectively. Continuously the mean arterial blood 
pressure and vital signs of the animals during challenge were monitored. For some 
experiments, rats were treated with Icatibant (Jerini, Berlin, Germany; 100 µg/kg bw) 
prior to heparin challenge. Frozen cross-sections of the A. femoralis and V. femoralis 2 
mm caudal to the knee joint were stained with Haematoxylin-Eosin (Sigma) 30 min 
after heparin application. Heparin-induced bradykinin generation in rats resulted from 
collaboration with B. Lecher and was published before in Oschatz et al., 2011. 
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4.2.7 Analysis of vascular leakage 
4.2.7.1 Miles edema model 
Mice were anesthetized by i.p. injection of Avertin (2,2,2-tribromoethanol and 2-methyl-
2-butanol; Sigma; 15 µL/g bw of a 2.5% solution with PBS) (Oschatz et al., 2011). 
Evans blue (Sigma; 10 µL/g bw of a 0.25% solution with 0.9% NaCl; Braun, 
Melsungen, Germany) was injected intravenously in the retro-orbital. 5 min later, dorsal 
skin edema was induced by intradermal injections. To avoid irritation of the skin, hairs 
were griped with a forceps close to the root, slightly raised and set back to see the skin. 
For injection a single-use 1 mL syringe with a 30 G needle (unimed, Lausanne, 
Switzerland) was used. The needle tip was bent to a hook, gently punched into the skin 
and turned sideways to inject 50 µL of MC-heparin (1 mg/mL), C48/80 (50 µg/mL), 
NaCl, histamine (Sigma; 100 µM), BK (Sigma, 100 µM) or heparinase-treated MC-
heparin (Miles and Miles, 1952). 10 mg/mL MC-heparin were incubated for 24 h at 
25°C with 5 U heparinase (Sigma). Some WT mice were pretreated with H-D-Pro-Phe-
Arg-chloromethylketone (PCK; Bachem, Bubendorf, Switzerland; 8 µg/g bw), Icatibant 
(100 µg/kg bw), or NaCl 5 min prior to MC-heparin injection. After 30 min, the mice 
were sacrificed, the skin was cut and tight attached on a flat surface. After 5-10 min the 
skin was photographed. The edema sites were excised using a circular template of 1.2 
cm diameter. For edema with diameter >1.2 cm the entire blue area was excised by 
hand (Oschatz et al., 2011). The edema-skins were cutted in little pieces. 
The Evans blue dye was extracted by incubation in 800 µL N,N-dimethylformamide 
(Sigma) overnight at 57°C (Donelan et al., 2006). After centrifugation at 20.000 rpm for 
1 h, the supernatant was collected. On a 96-well plate (UV-star, Greiner bio-one, 
Stuttgart, Germany) the Evans blue fluorescence of 100 µL sample (double 
determination) was quantified photometrically (multiple reader Victor2, PerkinElmer, 
Rodgau, Germany) at an excitation wavelength of 620 nm and an emission wavelength 
of 680 nm. The concentration of Evans blue was normalized by dividing with the value 
of NaCl-induced signal in WT mice (set to 1.0).  
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4.2.7.2 Skin vascular leakage assay  
To analyze vascular leakage in real time using intravital laser scanning microscopy, the 
method was used, which was originally described for leukocyte infiltration into vascular 
lesions (Eriksson et al., 2001; Oschatz et al., 2011). Mice were anesthetized by i.p. 
injection of Avertin (Oschatz et al., 2011). 3 ng/g bw FITC-dextran (150 kDa, Sigma) 
was injected into the retro-orbital plexus as tracer (Oschatz et al., 2011). Mice were 
placed on a cork plate in a supine position. A ventral skin window from the middleline of 
the abdomen to one side was excised and the skin was fixed plain next to the mice. 
Extravasation of tracer was started by topical application of MC-heparin (20 µL of a 1 
mg/mL solution). After 1 min the drop was removed from skin with soft paper without 
touching the skin. Extravasation of tracer from microvessels (35–60 µm diameter) was 
visualized using a Nikon Eclipse E600 microscope equipped with a C1 laser scanning 
head and a 10x objective (Nikon, Düsseldorf, Germany) (Oschatz et al., 2011). 
Leakage was assessed for 3 min before and 30 min after topical application of MC-
heparin (Oschatz et al., 2011). Tissue scans were performed at 30 sec intervals 
(Oschatz et al., 2011). Images were analyzed by EZ-C1 2.10 software (Nikon) and the 
intensity of extravasated tracer was quantified using ImageJ 1.34 NIH software 
(Oschatz et al., 2011). 
 
4.2.8 Anaphylaxis models 
4.2.8.1 Passive cutaneous anaphylaxis 
Mice were anesthetized by i.p. injection of Avertin. To induce passive cutaneous 
anaphylaxis, mice were sensitized by intradermal injection of anti- dinitrophenyl IgE (α-
DNP IgE; Sigma; 50 µL of a 1.5 µg/mL solution) or 50 µL steril 0.9% NaCl (control) in 
the dorsal skin (Oschatz et al., 2011). Intradermal injection was carried out as in the 
Miles edema model (Oschatz et al., 2011). After 20 h mice were challenged by retro-
orbitally injection of dinitrophenyl-human serum albumin (DNP-HSA; Sigma; 7.5 mg/kg 
bw) together with Evans blue (10 µL/g bw of a 0.25% solution with 0.9% NaCl) 
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(Siebenhaar et al., 2008; Oschatz et al., 2011). After 30 min, the mice were sacrificed, 
the skin was removed and photographed. The entire edema site was excised by hand. 
The Evans blue dye was extracted by incubation in N,N-dimethylformamide overnight 
at 57°C (Donelan et al., 2006). After centrifugation at 20.000 rpm for 1 h, the 
supernatant was collected and the Evans blue fluorescence was quantified 
photometrically at an excitation wavelength of 620 nm and an emission wavelength of 
680 nm.  
 
4.2.8.2 Passive systemic anaphylaxis 
For passive systemic anaphylaxis model, mice were injected with α-DNP IgE (1.25 
µg/g bw) into the tail vene, after they were placed under a red light for 10 min (Oschatz 
et al., 2011). 24 h later mice were challenged by injection of 1 mg DNP-HSA (Sigma) 
into the tail vene (Oschatz et al., 2011). For some experiments arterial blood pressure 
was recorded by fluid-filled catheter connected to a pressure transducer (APT 300, 
Harvard Apparatus, March-Hugstetten, Germany) (Oschatz et al., 2011). In other cases 
5-10 min after induction of systemic anaphylaxis animals were killed by Isofluran 
(Baxter, Unterschleiβheim, Germany) and blood was taken by cardial puncture. 
 
4.2.9 Generation of Serping1-/- mice 
A DNA archive from ENU-mutagenised, C3HeB/FeJ male mice (Augustin et al., 2005) 
was screened for point mutations in the C1INH gene (Serping1) by polymerase chain 
reaction amplification of the respective chromosomal coding regions followed by 
heteroduplex analysis of the generated fragments using a temperature gradient 
capillary electrophoresis system. Fragments displaying typical heteroduplex migration 
patterns were sequenced to determine the nature of the nucleotide substitution. In one 
animal, a guanine (g) to adenine (a) transition at position +1 in the splice donor site of 
Serping1 intron 2 was detected (Figure 4).  
 
Figure 4. Schematic representation of 
the Serping1 gene. Exons are shown as 
dark boxes. Serping1-/- mice have a single-
base transition (g to a) at position +1 in the 
donor splice site of Serping1 intron 2 
(Oschatz et al., 2011). 
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Sperm from the mutant carrier animal was used for in vitro fertilization of C3HeB/FeJ 
WT oocytes and the embryos were transferred to foster females. The resulting pups 
were genotyped for the presence of the mutation and bred to produce homozygous 
progeny. A coupled reverse transcriptase-PCR on total RNA from the mutants showed 
that the mutation causes exon 2 to be removed during Serping1 mRNA processing. In 
addition, elimination of exon 2 in the Serping1 mRNA causes a frame-shift, which leads 
to the early termination of protein synthesis during translation. The generation of 
Serping1-/- mouse resulted from collaboration and was kindly provided by Reinhard 
Sedlmeier and was published before in (Oschatz et al., 2011). 
 
For genotyping of Serping1-/- mice genomic DNA was isolated from mouse tails using a 
DNeasy blood & tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. For PCR a Taq DNA Polymerase Kit (Qiagen) was used. PCR reactions 
were performed in total volume of 25 µL containing 2.5 µL Taq buffer, 5 µL Q-solution, 
0.8 µM each of forward and reverse primer (forward primer C1Inh_1_for: 5´-
CTGGCTCTGAGGCTAACTGG-3´; reverse primer C1Inh_1_rev: 5´-
GAGAGGCTTCCCTCCTTCAC-3´; Eurofins, Ebersberg, Germany), 0.4 mM dNTP mix 
(Fermentas), 5 U Taq Polymerase and 50-100 ng DNA. The cycling condition were: 
preincubation at 94°C for 3 min, 59°C for 40 sec and 72°C for 1 min, 34 cycles of: 
denaturation step at 94°C for 45 sec, annealing step at 55°C for 45 sec and elongation 
step at 72°C for 45 sec. Final elongation step was at 72°C for 10 min. PCR fragments 
were separated by gelelectrophoresis on 1% agarose gel. Agarose was boiled in TAE-
buffer (Tris Acetate-EDTA buffer; Sigma), for DNA staining 0.1 µL/mL GelRed Nucleic 
Acid Stain (Biotium/VWR international) was added, and gels casted in appropriate 
chambers. PCR samples were diluted with 6x loading dye solution (Fermentas) and 
Gene Ruler 100 bp DNA Ladder Plus (Fermentas) was used to determine fragment 
size (150 bp). After electrophoresis at 120 V for 30 min, DNA separation and fragment 
sizes were analyzed with an UV transilluminator (Chemi Genius2, Syngene, VWR 
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international). Before sequencing PCR products were isolated from agarose gels by 
QIAquick PCR Purification Kit (Qiagen). To analyze for pointmutation in murine DNA 
PCR samples were sequenced with the C1Inh_1_for primer using Operon/Eurofins 
sequencing service or sequencing service from the Karolinska Institute (KIgene, 
Stockholm, Sweden). A guanine at position +1 in the splice donor site of Serping1 
intron 2 classifies the analyzed animal as a WT, an adenine implicates a Serping1-/- 
mouse. 
Antibodies against murine C1INH (-C1INH)  were generated by immunization of two 
rabbits using the peptide Cys-Asp23-Pro24-Glu25-Ala26-Thr27-Ser28-His29-Ser30-Thr31-
Gln32-Asp33-Pro34-Leu35-Glu36–Amid. A Cys was N-terminal and an amid was C-
terminal linked to the peptidsequence of murine C1INH (NP_033906). Peptidsynthesis 
and immunization was performed by BioGenes (Berlin, Germany). Before immunization 
pre-immune serum of each rabbit was collected for control. Immunizations, boosts, and 
collections of antisera were performed by standard protocols of BioGenes. After 
repeated boosting the animals were final bled to obtain sera. To control the presence of 
-C1INH in rabbit sera plasma of human and mice (from WT and Serping1-/-) was 
tested by Western blotting using 12% polyacrylamide gels. Western blotting detected α-
C1INH Ab only in one rabbit (number 3312). 
For immunoselection of -C1INH Ab 2.4 mg of peptide dissolved in 10 mM sodium 
bicarbonate (pH 7.4; Roth) were coupled to an Affi-Gel 10 column (Bio-Rad) overnight. 
All steps were performed at 4°C. The column was washed five-times with water, two-
times with wash buffer (2 M NaCl (Roth), 100 mM sodium acetate, pH 4 (Roth)), 
blocked with 1 M ethanolamine (pH 8) for 1 h, washed three-times with water and four-
times with TBS (20 mM Tris, pH 7, 15 mM NaCl). Serum was diluted 1:1 with TBS and 
the mixture was incubated with the column overnight. The column was washed three-
times with 10 mL of TBS, TBS-T and TBS, respectively. Thereafter, 1 mL fractions 
were eluted with elution buffer (200 mM glycine, pH 2, 150 mM NaCl) and 0.1 M Tris 
(pH 9) was immediately added. For regeneration the column was washed five-times 
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with PBS at RT. Eluted fractions were analyzed using SDS-page and Western blotting 
on 12% polyacrylamide gels. In fractions containing -C1INH the buffer was 
exchanged with PBS with Econo-Pac 10DG columns from Bio-Rad according to the 
manufacturer’s instructions. 
α-C1INH Ab specifically detected C1INH in WT mouse plasma migrating with an 
apparent molecular weight of 94 kDa in SDS-PAGE. C1INH protein was not detectable 
by immunoblotting using Ab against C1INH in the plasma of Serping1-/- mice (Figure 5; 
(Oschatz et al., 2011). 
 
 
 
 
 
 
 
 
 
4.2.10 Design of Hereditary angioedema type III patient survey 
Thirty-eight hereditary angioedema patients of the Kantonsspital Luzern, Switzerland, 
with symptomatic deficiency in functional C1INH (<30% C1INH activity, 37 HAE type I, 
1 patient with HAE type II, average age 40 years; 15 men 23 females of 11 families) 
were surveyed using the patient charts present at the outpatient clinic that was 
completed with a standardized questionnaire for which information was collected by 
personal or telephone interview. Diagnosis of allergic reactions was made based on 
clinical symptoms validated by experienced trained physicians. In patients with allergic 
reactions, allergens that trigger HAE attacks were identified using skin tests (prick test). 
Thirty-six patients suffered from abdominal edema and in 4 of them that was the sole 
symptom. 32 and 12 patients had edema in the skin and in the upper respiratory 
system, respectively. Ethical approval was granted from the ethical commission of the 
Figure 5. Analysis of murine C1INH 
expression. Human plasma (left lane), plasma 
from wild-type (WT) mouse (middle lane, 94 kDa) 
and Serping1-/- mouse plasma (right lane) was 
loaded. The unspecific signal of albumin (70 kDa) 
indicates equal lane loading (Oschatz et al., 
2011). 
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Kanton Luzern and all patients had given informed consent. Design of Hereditary 
angioedema type III patient survey resulted from collaboration with W.A. Wuillemin and 
was published before in (Oschatz et al., 2011). 
 
4.2.11 Generation of hereditary angioedema type III transgenic mice 
1. Insertion of human FXII cDNA into TOPO TA vector.  
cDNA from human FXII (rzpd, Berlin, Germany; MIM ID: 610619) was amplified using 
an Advantage-HF 2 PCR Kit (TaKaRa/Clontech, Saint Germain en Laye, France; High-
Fidelity (HF)). PCR reaction was performed in 50 µL reaction volume containing 5 µL 
HF buffer, 10 µM each of forward and reverse primer (forward primer HindIII: 5´-
GTATAAGCTTGATCTGGACTCCTGGATAGG-3´; reverse primer XbaI: 5´-
GTAATCTAGAGGGGAATGGGACACAATCTT-3´; Eurofins), 10 mM dNTP mix, HF 
Polymerase and 100 ng cDNA of human FXII. The PCR program was: preincubation at 
94°C for 2 min, 30 cycles of 94°C for 30 sec and 68°C for 2 min. Final step was 68°C 
for 3 min. Amplified FXII of 1.8 kbp were separated by gelelectrophoresis, and 
extracted from gel by QIAquick Gel Extaction Kit (QIAGEN). FXII was inserted into a 
TOPO TA vector (Invitrogen, Karlsruhe, Germany) using the TOPO TA cloning Kit 
(Invitrogen) following manufacturer´s instructions to generate the TOPO TA_FXII 
vector. 
 
2. Generation of FXII pointmutation in TOPO TA_FXII vector 
1032C→A pointmutation was generated in FXII in the TOPO TA_FXII vector by site-
directed mutagenesis using QuikChange Multi Site-directed Mutagenesis Kit 
(Stratagene, Amsterdam, the Netherlands). The mutagenic FXII-Thr328Lys primer (5`-
CCGAAGCCTCAGCCCAAGACCCGGACCCCGCCTCAG-3´, sequence variation with 
respect to the FXII cDNA is in bolt; TIB MOLBIOL, Berlin, Germany) was employed to 
exchange C 1032 with A. PCR reaction was performed in 25 µL reaction volume 
containing 2.5 µL QuikChange Multi reaction buffer, 0.5 µL QuikSolution, 100 ng TOPO 
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TA_FXII vector, 0.64 µM mutagenic FXII-Thr328Lys primer, 10 mM dNTP mix and 2.5 
U/µL QuikChange Multi enzyme blend. For PCR preincubation at 95°C for 1 min, 30 
cycles of denaturation step at 95°C for 1 min, annealing step at 55°C for 1 min and 
elongation step at 65°C for 11 min were performed. Resulting TOPO TA vector with a 
1032C→A mutated human FXII was named TOPO TA_FXIIThr328Lys. Following the 
manufacturer´s instructions (Stratagene) the vector was demethylated with 15 U DnpI 
for 2 h at 37°C. 
 
3. Subcloning of mutated FXII from TOPO TA_FXIIThr328Lys vector into pcDNA3 
vector.  
Restriction digestion of the TOPO TA_FXIIThr328Lys vector and pcDNA3 vector 
(Invitrogen) were performed in 50 µL reaction volumes, each, containing 5 µg DNA, 5 
µL restriction buffer 2, 5 µL BSA and 40 U of restriction enzymes HindIII (5`) and XbaI 
(3´) (NEW ENGLAND BioLabs, Frankfurt, Germany). Reactions were incubated at 
37°C for 3 h. After restriction digestion fragment size were controlled with agarose 
gelelectrophoresis. Mutated FXII (1.8 kbp) and cleaved pcDNA3 vector (5.4 kbp) were 
extracted from gel using QIAquick Gel Extaction Kit (QIAGEN). Ligation of 50 ng 
mutated FXII fragment with 50 ng pcDNA3 vector was set up in a 20 µL reaction 
volume using 2 µL T4 DNA ligase buffer and 400 U T4 DNA ligase (NEW ENGLAND 
BioLabs). Ligase reaction was incubated 5 min at RT resulting in 
pcDNA3_FXIIThr328Lys vector. Ligase reaction was controlled by restriction digestion. 
pcDNA3_FXIIThr328Lys vector was transformed into competent E. coli (One shot 
TOP10 Competent Cells; Invitrogen) according to manufacturer´s instructions. 
Transformed E.coli were grown over night at 37°C on agar plates (Lysogeny broth 
medium (1 % (w/v) tryptone (Roth), 0.5 % (w/v) bacto yeast extract (Roth), 1 % (w/v) 
NaCl, pH 7.0) and 1.5 % (w/v) agar (Roth)) in the presence of 100 µg/mL ampicillin 
(Sigma). pcDNA3_FXIIThr328Lys plasmid DNA was isolated from exponentially 
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growing bacterial culture (at 37°C shaking at 200 rpm; OD600 = 0.6) according to 
manufacturer´s instructions (QIAfilter Kit for plasmid purification, Qiagen). 
 
4. Subcloning of mutated FXII from pcDNA3_FXIIThr328Lys into pTRE-Tight vector. 
Restriction digestion of both, pcDNA3_FXIIThr328Lys plasmid and pTRE-Tight vector 
(TaKaRa/Clontech) was performed for 3 h at 37°C in a 100 µL reaction volume 
containing 10 µL BSA, 10 µL buffer 2, 13 µg pcDNA3_FXIIThr328Lys vector, 40 U 
HindIII (5`) and 40 U EcoRV (3`) (NEW ENGLAND BioLabs). After restriction digestion 
fragment size was controlled with agarose gelelectrophoresis and fragments were 
extracted from the gel. FXIIThr328Lys DNA fragment (1.8 kbp) was ligated with pTRE-
Tight vector (2.6 kbp) to pTRE-Tight_FXIIThr328Lys. 20 µL ligation volume contained 
50 ng pTRE-Tight plasmid vector, 104 ng FXIIThr328Lys DNA fragment, 2 µL Ligase 
buffer and 400 U T4 DNA Ligase. The reaction batch was mixed, incubated for 30 min 
at 16°C and used for transformation. Map of pTRE-Tight_FXIIThr328Lys vector is 
shown in Figure 6. pTRE-Tight_FXIIThr328Lys plasmid DNA was isolated from bacteria 
culture. Size of FXII, sequence of human FXII according to MIM ID: 610619 and 
1032C→A pointmutation were confirmed by control restriction digestion and DNA 
sequence analyses using Operon/Eurofins sequencing service (Eurofins). 
 
  
 
 
 
Figure 6. Map of pTRE-Tight_FXIIThr328Lys vector. The vector contains a Tet-responsive promoter, 
the 1032C→A mutated human FXII and an ampicillin resistence gene. Location of forward and reverse 
primer (HAE III_geno_Pfor_1, HAE III_geno_Prev_4) for genotyping of HAE III mice is indicated. 
Description of containing features is given in boxes. Recognition sites of restriction enzymes are indicated 
without boxes. Positions in the vector are given in numbers of bp. 
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5. Generation of a HAE III mouse 
To generate a HAE III mouse pTRE-Tight_FXIIThr328Lys vector was isolated from E. 
coli bacteria cultures (QIAflter Kit for plasmid purification, Qiagen). Restriction 
digestion, agarose gelelectrophoresis and sequencing analysis (Eurofins) confirmed 
the right size of 1.8 kbp, sequence and the 1032C→A pointmutation of the human FXII, 
before the vector was send to the Institute of Experimental Pathology, Münster, 
Germany. HAE III mouse was generated via oocytes injection of pTRE-
Tight_FXIIThr328Lys plasmid after linearization with BspHI (5´) and BspLU11I (3`) 
(Figure 6). 31 pups were born. For genotyping of HAE III mice the genomic DNA was 
isolated from mice tails with a DNeasy blood & tissue Kit (Qiagen). For PCR a Top Taq 
DNA Polymerase Kit (Qiagen) was used. PCR reactions were performed in 25 µL 
reaction volume containing 2.5 µL Top Taq buffer, 5 µL Q-solution, 0.8 µM each of 
forward and reverse primer (forward primer HAE III_geno_Pfor_1: 5´-
CGTATGTCGAGGTAGGCGTG-3´; reverse primer HAE III_geno_Prev_4: 5´-
CACAAATGTACCCACAAGGGCCGGC-3´; Eurofins; Figure 6), 0.4 mM dNTP mix, 5 U 
Top Taq DNA Polymerase and 50-100 ng genomic DNA. The cycling condition were: 
preincubation at 94°C for 3 min, 30 cycles of denaturation step at 94°C for 30 sec, 
annealing step at 58°C for 30 sec and elongation step at 72°C for 1 min. Final 
elongation step was at 72°C for 10 min. Mutated FXII fragments of 359 bp of transgenic 
mice were separated by gelelectrophoresis on 1 % agarose gel. 3/31 (10%) of the pups 
carried the transgene.  
 
4.2.12 Data analysis 
All data were represented as means ± SD. Statistical analyses were performed using 
the one-way ANOVA, followed by Dunnett´s post test. P-values < 0.05 were considered 
statistically significant (Oschatz et al., 2011). 
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5 RESULTS 
5.1 Mast cell-heparin activates the contact system in plasma 
High molecular heparin (500-750 kDa) was isolated from rat peritoneal MC and the 
potency of the glycosaminoglycans for BK generation was analyzed. Human plasma 
was incubated with increasing amounts of MC-heparin and analyzed for HK processing 
and BK formation by Western blotting and ELISA, respectively. Antibodies against the 
BK sequence in HK revealed that ≥4 µg/mL MC-heparin initiated complete plasma HK 
cleavage (Figure 7A, upper panel). Consistently, BK was high (>780 ng/mL) in these 
samples, but low in those treated with buffer (37 ± 22 ng/mL) or with ≤2 µg/mL MC-
heparin (<35 ng/mL), which was not sufficient to initiate HK processing (Figure 7A, bar 
graph). As a control, MC-derived glycosaminoglycans were incubated with heparinase 
(Hase) before adding them to plasma. The enzyme specifically digests heparin. Hase-
treatment largely abolished BK formation, triggered by activated MC-released material. 
HK conversion started at >30-fold higher concentrations of the digested (≥128 µg/mL, 
Figure 7B) vs. non-treated glycosaminoglycans, indicating that heparin accounts for 
most of the BK-forming activity in MC-released material. Heparin induces the reciprocal 
activation of FXII and PK in ice-cold plasma (Hojima et al., 1984). Consistent with this 
observation, MC-heparin failed to initiate HK cleavage and BK production in FXII or PK 
deficient plasma at physiological temperature (Figure 7C). In contrast, deficiency of the 
FXII substrate in the intrinsic coagulation pathway, FXI, did not interfere with HK 
processing (Figure 7C, lane 2). MC-heparin added to normal plasma induced the 
contact system cascade with sequential proteolytic activation of FXII, PK and HK, but 
not of LK (a kininogen gene splice variant that does not bind PK) or FXI (Figure 7D). 
Efficient contact system activation depends on negative charge density and the size of 
the FXII-binding surface  (Muller and Renne, 2008).1
                                                      
1 The text of the whole page is taken from the publication Oschatz et al., 2011. 
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Figure 7. MC-derived heparin initiates contact system-mediated BK formation. Human plasma was 
incubated for 30 min at 37°C with MC-derived glycosaminoglycans and analyzed for single-chain HK by 
Western blotting, and for BK formation by ELISA (means ± SD, n=8). Glycosaminoglycans at ≥4 µg/mL 
initiated plasma HK cleavage and BK formation (A). MC-derived glycosaminoglycans were incubated with 
heparinase (Hase) prior to addition of plasma (B). Plasma deficient in FXII, FXI, or PK and normal plasma 
(NP) was incubated with 20 µg/mL MC-heparin for 30 min and analyzed for HK cleavage and BK liberation 
(C). Left: Schematic drawing of MC-heparin triggered reaction cascade, which forms BK by FXII/PK-
mediated HK processing. Right: Buffer- (w/o) and heparin-treated (heparin) plasma was probed for FXII, 
PK, single-chain HK, LK, and FXI zymogen, respectively (D) (Oschatz et al., 2011). These data resulted 
from a collaboration with T. Renné. 
MC-heparin and heparan sulfate were compared for their ability to release BK from HK. 
Both polysaccharides have similar backbones consisting of alternating iduronic acids 
and glucosamines, but differ in charge (heparin has an average of 2.7 sulfate  per 
groups typical disaccharide unit, whereas heparan sulfate has an average of 1.0;2  
                                                      
2 This text section is taken from the publication Oschatz et al., 2011. 
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(Capila and Linhardt, 2002)). Human plasma was incubated with increasing amounts of 
MC-heparin, heparan sulfate and the synthetic polysaccharide dextran sulfate potent  
FXII activator; (Johne et al., 2006), respectively (Figures 8A - 8C). MC-heparin and 
dextran sulfate at ≥10 µg/mL each, triggered complete conversion of plasma HK. In 
contrast, heparan sulfate up to 100 µg/mL did not induce HK cleavage and high3 
                                                      
3 This text section is taken from the publication Oschatz et al., 2011. 
Figure 8. MC-heparin-induced BK formation is dependent on the negative charge density of the 
polyanion. Human plasma samples were supplemented with 1 to 1000 µg/mL heparin (A), heparan sulfate 
(B), dextran sulfate (C), heparan sulfate sulfated for 1 min (D) or 10 min (E) and desulfated heparin (F), 
respectively, incubated for 30 min at 37°C, and analyzed for HK cleavage and BK formation by Western 
blotting and ELISA, respectively. Means ± SD, n=8 are plotted (Oschatz et al., 2011). These data resulted 
from a collaboration with T. Renné and B. Lecher. 
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concentrations (1000 µg/mL) of the glycosaminoglycan only induced minor HK 
cleavage (36% of total plasma HK, corresponding to 260 ng/mL BK). To demonstrate 
that negative charge density, rather than a defined structure of the polysaccharide is 
responsible for the enhanced BK-generating potency of heparin as compared to 
heparan sulfate, heparan sulfate was sulfated with sulfuric acid/carbodiimide. This 
method does not cause depolymerization of the polysaccharide. Hypersulfation 
increased the BK-forming activity of heparan sulfate (Figure 8D). After 10 min sulfation, 
the activity of treated heparan sulfate was similar to heparin (compare Figure 7E vs. 
8A). In contrast, chemical desulfation of heparin with N,O-bis(trimethylsilyl)acetamide 
largely abolished its BK-forming activity (Figure 8F). Together, the data show that MC-
heparin initiates BK formation in plasma via activation of the contact system.4 
 
 
5.2 Mast cell-heparin competes with high molecular weight kininogen for 
            binding to cells 
BK formation is tightly regulated and HK binding to the cell surface heparan sulfate-
type proteoglycans protects the BK-precursor from proteolysis (Renne et al., 2005b). 
Because both heparin and heparan sulfate bind to the cell-binding site in HK (Leeb-
Lundberg et al., 2005) MC-heparin might detach cell-bound HK from heparan sulfates 
as a prerequisite for efficient BK formation. To test this hypothesis, EA.hy926 
endothelial cells were incubated with 60 nM radiolabeled, uncleaved HK, removed 
unbound HK was removed and HK deficient plasma supplemented with MC-heparin 
were added (0.05-200 µg/mL). This experimental design analyzes cell-bound HK in the 
absence of HK in the fluid phase. Following incubation, cell-bound HK, HK cleavage, 
and BK formation were monitored. Heparin dose-dependently reduced HK-cell binding; 
at ≥4 µg/mL polysaccharide, cell-bound HK was reduced to <20% of levels measured5 
                                                      
4 This text section is taken from the publication Oschatz et al., 2011. 
5 This text section is taken from the publication Oschatz et al., 2011. 
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in the absence of heparin (set to 100%; Figure 9A). HK detachment from cells was 
associated with HK cleavage (Figure 9B) and BK formation (Figure 9C).6
                                                      
6 These two lines are taken from the publication Oschatz et al., 2011. 
Figure 9. MC-heparin detaches HK from endothelial cells and induces BK release. Uncleaved 
radiolabeled HK (60 nM) bound to EA.hy926 cells was incubated with 0.05 - 200 µg/mL heparin in HK 
deficient plasma. Following incubation for 30 min at 37°C, the samples were analyzed for HK cell binding, 
HK cleavage, and BK formation. The cellular [125I]-HK binding capacity was monitored by a γ-counter and 
normalized for HK binding in the absence of heparin (set at 100%) (A). Cleavage of HK was analyzed by 
Western blotting using antibodies against the BK sequence (MBK3). The relative levels of uncleaved HK, 
determined from Western blot signal intensities are given below (untreated control set at 100%) (B). ELISA 
measured BK in cell supernatants (C). Means ± SD of 5 independent experiments are shown (Oschatz et 
al., 2011). These data resulted from collaboration with T. Renné. 
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5.3 Mast cell-heparin activates the contact system in rodents. 
To test MC-heparin for triggering BK generation in rodents, the polysaccharide was 
infused into the femoral artery of rats and BK formation was analyzed by ELISA. 
Heparin injection greatly increased plasma BK (224 ± 93 ng/mL) over buffer-treated 
animals (23 ± 16 ng/mL). BK generation was associated with leukocyte adhesion to 
vessel walls, as shown in limb cross-sections from animals that were sacrificed 30 min 
after challenge (Figure 10A). Leukocyte-endothelial cell adhesion was restricted to 
femoral artery vessel walls downstream of the injection site and to the ipsilateral vena 
femoralis. At some sites, leukocytes had penetrated the endothelial border and invaded 
into subendothelial tissues (Figure 10B). To confirm that BK mediates MC-heparin-
triggered leukocyte adhesion, we treated rats with the B2R antagonist Icatibant (Wirth 
et al., 1991) prior to heparin infusion. Icatibant did not alter heparin-induced BK plasma 
levels (181 ± 72 ng/mL) but almost completely blunted leukocyte adhesion to vessel 
walls (Figures 10C and 10D). In addition to being a chemoattractant for neutrophils, BK 
is a potent vasodilator  (Leeb-Lundberg et al., 2005). Intraarterial MC-heparin infusion 
induced a rapid (within 45 sec), pronounced (≈160 to 50 mmHg) and reversible drop in 
blood pressure. Blood pressure recovered close to baseline levels within 30 min. 
Heparin-triggered hypotonic reaction was almost completely blocked by Icatibant 
(Figure 10E). In contrast to intraarterial application, subcutaneous or intravenous 
injection of MC-heparin up to 25 mg/kg bw did not change blood pressure nor trigger 
leukocyte adhesion (not depicted). 
To evaluate the role of MC-heparin-driven BK formation for allergic reactions we 
challenged wild-type, FXII deficient (F12-/-) and B2R deficient (Bdkrb2-/-) mice that are 
defective in BK generation (Pauer et al., 2004) or BK signaling (Borkowski et al., 1995), 
respectively, in a model of passive systemic anaphylaxis. We injected mice 
intravenously with α-DNP IgE and challenged them 24 h later with an intravenous 
injection of DNP-HSA. WT mice responded with a rapid7 and transient drop in systemic 
                                                      
7 The text of the whole page is taken from the publication Oschatz et al., 2011. 
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Figure 10. MC-heparin induces BK-driven leukocytes infiltration and 
hypotension in rodents. Heparin was infused into the left femoral artery of 
untreated (w/o) or Icatibant (Icat) treated rats and the animals were sacrificed 
30 min after challenge. Hematoxylin and eosin stained cross- sections of limb 
vessels dorsal to the heparin infusion site are shown. Leukocytes adhere to 
vessel walls (green arrows) in untreated animals (A) and transmigrate through 
arterial blood pressure of 57 ± 24 mmHg, whereas allergen-induced hypotonic 
response was decreased in F12-/- (23 ± 10 mmHg) and Bdkrb2-/- (27 ± 13 mmHg) 
mice.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
8 This text is taken from the publication Oschatz et al., 2011. 
the endothelial barrier (asterisk,higher magnification) (B).Corresponding sections of Icat-treated animals 
are shown in (C) and at higher magnification in (D). Bar is 250 µm in A and C, and 10 µm in B and D. 
Representative histology of n=7 rats in each group is shown. Heparin was injected into the aorta of rats 
and the mean arterial blood pressure was measured in the left carotid artery in untreated- (red line) or 
Icat-pretreated rats (blue line). The times of Icat and heparin administration are indicated by white and 
black triangles, respectively. Means ± SD, n=7 rats (E). Arterial blood pressure during IgE/Ag-induced 
systemic anaphylaxis in WT (red), F12-/- (black) and Bdkrb2-/- (green) mice or WT mice pretreated with 
PCK (gray) or Icat (blue). Infusion of Icat or PCK and DNP-HSA is symbolized by white and black 
triangles, respectively. Means ± SD of 10 mice per group are displayed (F). Western blot analyses of 
plasma using antibodies against HK (non-processed single-chain HK, upper row), the BK sequence in HK 
(middle row), and FXI (lower row) in plasma of IgE/Ag- (lane 1), IgE/buffer-challenged (lane 2), and 
untreated mice (w/o; lane 3) (G) (Oschatz et al., 2011). The data of 11A-F resulted from collaboration with 
B. Lecher. 
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HK cleavage and BK release in plasma of IgE/Ag-challenged mice were analyzed. Ten 
min after antigen infusion BK was released from circulating HK in anaphylactic mice 
(Figure 10G).  
WT mice pretreated with either FXII-inhibitor PCK (Kleinschnitz et al., 2006) or Icatibant 
were protected from IgE/antigen (Ag)-mediated drop in blood pressure (25 ± 10 and 29 
± 12 mmHg; Figure 10F). The aPTT is a commonly used diagnostic coagulation test to 
measure heparin plasma activity. IgE/Ag challenge largely prolonged the aPTT9 
compared to IgE/buffer-infused control mice. Indeed, plasma samples from 
anaphylactic mice (n=15) did not clot at all (clotting times >180 seconds vs. 46 sec in 
buffer treated animals) indicating considerable heparin release (exceeding the amount 
used in anticoagulation therapy). A 1:10 dilution of plasma of anaphylactic mice with 
plasma of untreated mice led to a measurable prolongation of the aPTT (73.9 ± 24.2 
sec, n=10) corresponding to 4.7 ± 1.7 µg/mL heparin, 10 min after IgE/Ag challenge in 
undiluted plasma of IgE/Ag treated mice. This heparin concentration is sufficient to 
induce activation of FXII and PK, cleavage of HK, and BK formation (starting at >2 
µg/mL, Figure 7A). At 5 min after challenge, the systemic heparin concentration was 
0.8 µg/mL for C48/80 challenge and 2.1 µg/mL for IgE/Ag challenge, respectively. 
Addition of the heparin antidote protamine (Goto et al., 1984) reduced the aPTT (51.2 ± 
7 sec, n=5) close to levels of untreated control mice (46 ± 2 sec, n=15). Similarly, 
incubation of plasma of IgE/Ag treated mice with heparinase (the enzyme that blocked 
heparin-driven BK formation, Figure 7B) reversed the IgE/Ag-induced aPTT 
prolongation (57.3 ± 20.6 sec, n=5). As protamine- and heparinase reversed the 
prolonged aPTT during anaphylaxis, this shows that a considerable amount of heparin 
is released during anaphylaxis. Consistent with IgE/Ag challenge in mice, infusion of 
C48/80 significantly prolonged the aPTT (>3 fold over control). Since heparin is rapidly 
cleared from the circulation with a plasma half-life of approximately 60 min (Bjornsson 
and Levy, 1979), the coagulation assays probably underestimate the amount of 
                                                      
9 These four lines are taken from the publication Oschatz et al., 2011. 
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released heparin. Additionally, the local heparin concentration at the MC surface may 
largely exceed the measured systemic concentration of the polysaccharide. 
Cumulatively, the data show that MC derived-heparin initiates BK formation via the 
FXII-stimulated contact system and that this pathway contributes to MC-driven 
hypotonic reactions in systemic anaphylaxis in vivo.10 The data are consistent with 
heparin release and aPTT prolongation during anaphylactic reactions in patients (Mazzi 
et al., 1994; Lombardini et al., 2009). 
 
 
5.4 Mast cell-heparin increases microvascular permeability in a bradykinin-
dependent manner in mice 
A hallmark of BK-mediated effects is increased vascular permeability (Han et al., 
2002). To analyze contact system-mediated leakage in genetically altered mice, an 
intravital confocal scanning microscopy technique was established to visualize 
microvascular fluid efflux. Macromolecular FITC-dextran was intravenously injected as 
a tracer for paracellular extravasated plasma proteins. A ventral skin window was 
incised, skin was inverted and analyzed under the microscope. Fluorescence tracer 
showed blood flow in microvessels during the experiment. No basal tracer 
extravasation was detectable for 3 min prior to stimulation, indicating intact vascular 
barriers. Topical application of MC-heparin (time point 0 min) provoked leakage from 
capillaries in WT mice. First leaky spots appeared within 10 min and leakage was 
maximal after 20 min (tracer fluorescence intensity 67.1 ± 15.2-fold of initial t=0 min 
signal; Figure 11, column 1). To exclude that the increase in vascular permeability is 
mediated by a contaminant rather than by heparin, the polysaccharide was digested 
with Hase. Hase-treatment abolished the activity of the polysaccharide to increase 
vascular leakage in WT mice (1.6 ± 0.9-fold at 20 min; column 2). To exclude a11  
                                                      
10 These three lines are taken from the publication Oschatz et al., 2011. 
11 This text section is taken from the publication Oschatz et al., 2011. 
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contribution of released endogenous MC-heparin MC deficient mice (KitW-sh/W-sh) were 
tested. Exogenous MC-heparin-triggered leakage in MC deficient mice (64.2 ± 4.2; 
column 5) to similar levels as observed in WT animals. Because FXII-independent 
mechanisms for PK activation exist (Schmaier, 2008), we analyzed heparin-triggered 
leakage in F12-/- mice that are defective in contact system-driven BK formation (Pauer 
et al., 2004). Intravital microscopy showed that F12-/- animals were resistant to MC-
heparin-stimulated alterations in vascular permeability (1.6 ± 0.7, 20 min; column 3). To 
confirm that MC-heparin induces vascular leakage by releasing BK, Bdkrb2-/- mice 
were employed that are protected from BK-driven edema (Han et al., 2002). Bdkrb2-/- 
animals were mostly resistant to heparin-induced increase in permeability (1.7 ± 1.4, 20 
min; column 4). Histamine triggered leakage in F12-/- and Bdkrb2-/- mice (63.3 ± 8.7 and 
65.8 ± 11.8; column 7), indicating that these animals are susceptible for plasma contact 
system-independent edema formation. 
HAE is characterized by recurrent swelling attacks. The underlying disease mechanism 
is a deficiency in functional C1INH (Zuraw, 2008). In patients with inherited C1INH 
deficiency, poorly defined stimuli trigger contact system-driven excessive BK formation 
that increases vascular leakage (Davis, 2008). To generate an animal model for HAE, 
the Serping1 gene in mice was inactivated, as described in material and methods. 
Since MC contribute to allergic angioedema (Greenhawt and Akin, 2007), MC-heparin 
was investigated as a potential trigger for vascular leakage in C1INH deficient 
(Serping1-/-) mice. Intravital microscopy showed that MC-heparin provoked excessive 
vascular leakage in Serping1-/- vs. WT mice (compare column 6 vs. 1). Leakage began 
earlier (first leaky spots at 4.5 min vs. 10 min), was longer-lasting (>50 min) and was 
greatly increased in Serping1-/- over WT mice (113 ± 17.2 vs. 67.1 ± 15.2, t=20 min).12 
                                                      
12 The text of the whole page is taken from the publication Oschatz et al., 2011. 
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5.5  Mast cell-heparin induces contact system-driven edema in mice 
The relative importance of heparin-driven BK formation for MC-mediated leakage in 
mice was analyzed using the Miles edema model (Miles and Miles, 1952). 
Intradermally injected stimuli triggered leakage in dermal vessels that was visualized by 
Evans blue tracer. Extravasated tracer was extracted from the tissue, quantified by 
fluorescence emission and plotted relative to the NaCl-induced signal in WT mice (set 
to 1.0). Basal vascular permeability, assessed in NaCl injected skin, was low (≤1.2) in13  
                                                      
13 The last four lines are taken from the publication Oschatz et al., 2011. 
Figure 11. MC-heparin increases permeability of skin microvessels. Extravasation of FITC-dextran 
tracer from murine dorsal skin microvessels was recorded by intravital laser scanning fluorescence 
microscopy in real time. Heparin was topically applied to the skin of WT, F12-/-, Bdkrb2-/-, KitW-sh/W-sh and 
Serping1-/- mice (columns 1, 3-6). For control, heparinase (Hase) treated heparin was applied to the skin of 
WT animals (column 2) and histamine to F12-/- and Bdkrb2-/- mice (column 7). Laser scanning images were 
taken at 5, 10, 20 and 30 min after stimulation at time-point 0 min and are shown in false colors. White 
represents the highest tracer intensity. The scale bar represents 500 µm. Confocal images were recorded 
with a 10x objective and processed with software EZ-C1, version 2.10 for Nikon. A typical experiment of a 
series of n=10 mice per genotype is shown (Oschatz et al., 2011). 
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all tested mice. BK-stimulated leakage was similar in WT (Figure 12A) and F12-/- 
(Figure 12B) mice (4.2 ± 0.9 vs. 4.1 ± 0.7; Figure 12F) whereas Bdkrb2-/- animals were 
resistant to BK challenge (1.2 ± 0.5; Figures 12C and 12F). Heparin injection induced 
edema in WT animals (3.3 ± 0.8), whereas F12-/- and Bdkrb2-/- mice were almost 
completely resistant to heparin-induced leakage and edema was not significantly 
different from NaCl controls (1.3 ± 0.4 vs. 1.1 ± 0.3 and 1.1 ± 0.3 vs. 1.1 ± 0.2, Figure 
12F).14 
                                                      
14 This text section is taken from the publication Oschatz et al., 2011. 
Figure 12. MC-heparin initiates edema in a BK-dependent manner. Evans blue was infused 
intravenously as a tracer into WT (A), F12-/- (B), Bdkrb2-/- (C), KitW-sh/W-sh (D) and Serping1-/- (E) mice. 
Skin edema was induced by intradermal injections with BK, C48/80 and heparin or NaCl. Leakage 
was analyzed after 30 min. Spots with extravasated tracer were entirely excised, dye was extracted, 
and quantified. Tracer extravasation is plotted relative to leakage in WT mice stimulated with NaCl. 
Columns show means ± SD, n=10 per group (F) (Oschatz et al., 2011). 
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Since congenital deficiency in FXII and B2R provides protection from edema, 
pharmacological inhibition of BK formation was tested and signaling for interference 
with heparin-driven leakage. Infusion of PCK or Icatibant prior to challenge largely 
reduced heparin-induced edema in WT mice as compared to untreated animals 
(1.7 ± 0.5 and 1.5 ± 0.5 vs. 3.0 ± 0.6; Figure 13).  
 
  
 
Tracer measurements are consistent with the intravital microscopy data (Figure 13). 
Cumulatively, the data show that heparin is an activator of the contact system and that 
the polysaccharide initiates BK-driven edema in vivo. To determine the importance of 
heparin-initiated BK formation for activated MC-driven skin edema, animals were 
challenged with compound 48/80 (C48/80), a degranulator of MC and eosinophiles 
(Sher and Wadee, 1981). MC deficient mice were largely resistant to C48/80 
stimulation and leakage was low as in NaCl controls (1.1 ± 0.4 vs. 1.2 ± 0.3; Figures 
12D and 12F). In F12-/- animals C48/80-stimulated leakage was reduced to 2.3 ± 0.6-
fold that is 52% of WT mice level (4.4 ± 0.6; Figures 12B and 12F). Bdkrb2-/- mice 
confirmed that FXII-triggered BK formation, rather than other FXII-initiated pathways, is 
important for MC-induced edema. In these animals C48/80-provoked leakage was15 
                                                      
15 The whole text of this page is taken from the publication Oschatz et al., 2011. 
Figure 13. Pharmacological targeting of 
the contact activation system interferes 
with MC-heparin-induced edema in WT 
mice. Mice were intravenously injected 
with NaCl (w/o), FXIIa-inhibitor PCK (8 
µg/g bw), or B2R antagonist Icatibant 
(Icat, 175 µg/kg bw), respectively. Five 
min later, they received an intradermal 
injection of NaCl (left) or heparin (right) 
(A). Extravasated Evans blue tracer was 
determined 30 min after challenge and is 
shown relative to levels of NaCl-induced 
leakage in untreated WT animals. 
Columns give means ± SD of n=10 
animals per group (B) (Oschatz et al., 
2011). 
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reduced to 55% (2.4 ± 0.5-fold; Figures 12C and 12F) of WT mice levels. The data 
indicate that heparin-induced BK formation accounts for about half of the edema-
forming capacity of activated MC. To test heparin for triggering edema in HAE, the 
Serping1-/- mice were employed (Figures 12E and 12F). NaCl-induced leakage was 
1.2 ± 0.4-fold of WT mice, indicating that basal vascular permeability in Serping1-/- mice 
was not significantly different from that of WT animals (p > 0.05). In contrast, 
application of heparin or C48/80 triggered excessive edema that exceeded levels in 
WT mice by >45% and >60% (4.8 ± 0.7 and 18.1 ± 2.0), respectively, whereas BK-
driven edema was not significantly different from levels in WT animals (4.3 ± 0.6; 
p > 0.05).16 
To determine downstream BK signaling the role of its downstream target VASP was 
investigated and VASP deficient (VASP-/-) mice were employed. In the Miles edema 
model WT and VASP-/- mice were intradermally injected with BK and NaCl (control). 
Evans blue tracer extravasation revealed that BK-induced increase in vascular 
permeability was significantly increased in VASP-/- over WT mice (4.9 vs. 3.2-fold of 
NaCl; n=7; p < 0.05; Figure 14). The data indicate that VASP deficiency interferes with 
leakage suggesting a critical role of VASP formation for stability of tight junctions and 
vascular barrier integrity in BK-driven edema formation. 
 
 
 
 
 
 
 
 
 
                                                                                                                                                              
 
16 This text section is taken from the publication Oschatz et al., 2011. 
Figure 14. Function of VASP for 
endothelial barrier integrity. 
Evans blue tracer was intravenously 
injected into wild-type (WT) and 
VASP deficient (VASP-/-) mice. Skin 
edema formation was induced by 
intradermally injection of bradykinin 
(BK). NaCl was used as a control 
(A). After 30 min edema sites were 
excisted and the fluorescence of 
extravasated Evans blue was 
quantified. Values are blotted 
relative to NaCl injection. Colums 
show means ± SEM, n=7 per group 
(B) (Benz et al., 2008). 
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5.6  Allergen-stimulated mast cells induce bradykinin-mediated edema 
To further evaluate the role of the plasma contact system for MC-mediated skin edema 
under pathophysiological conditions, a model for passive cutaneous anaphylaxis, an 
IgE-dependent hypersensitivity reaction was set up (Siebenhaar et al., 2008). 
Histamine was applied as positive control and induced comparable leakage in the skin 
of WT, F12-/-, Bdkrb2-/-, KitW-sh/W-sh, and Serping1-/- mice (4.4 ± 0.5 - 4.8 ± 1.0-fold; 
Figure 15). In contrast, injected Hase-treated heparin failed to increase leakage over 
NaCl levels (1.1 ± 0.4 - 1.3 ± 0.4). Mice were topically sensitized by intradermal anti-
DNP IgE injection, challenged 20 h later with intravenous injection of DNP-HSA and 
extravasated tracer was analyzed after 30 min (Figure 15). Allergen exposure 
increased leakage in WT animals to 26.6 ± 5.0 (Figures 15A and 15F), whereas KitW-
sh/W-sh mice were resistant to IgE/Ag-mediated leakage (1.2 ± 0.4; Figures 15D and 
15F), supporting the specificity of the stimulus for MC-driven edema. Under the same 
conditions, edema was reduced to 14.6 ± 5.2 and 13.6 ± 6.6 in F12-/- and Bdkrb2-/- 
mice, respectively (Figures 15B, 15C and 15F). The cutaneous anaphylaxis model is 
consistent with data from C48/80-stimulated MC and supports a critical role of BK for 
sensitized MC-driven leakage.17 
                                                      
17 The whole text of this page is taken from the publication Oschatz et al., 2011. 
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Figure 15. BK contributes to edema in a mouse model of passive cutaneous anaphylaxis. Mice 
were intradermally injected with IgE or NaCl and challenged 20 h later by intravenous injection of DNP-
HSA and Evans blue tracer. The extravasation of Evans blue tracer dye after 30 min is shown in 
representative skins from WT, F12-/-, Bdkrb2-/-, KitW-sh/W-sh and Serping1-/- mice (A-E). Tracer was 
extracted from the entire edema site, tracer fluorescence was quantified and signal is plotted relative to 
NaCl-induced extravasated Evans blue in WT mice (Red-white dashed lines represent tracer intensity in 
a circle of 1.2 cm diameter within the edema). Means ± SD, n=10 per group are shown (F) (Oschatz et 
al., 2011). 
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5.7  Allergens exacerbate edema in C1 esterase inhibitor deficient mice and in 
            Hereditary angioedema patients  
To analyze allergen-stimulated MC for initiating edema in HAE, Serping1-/- mice were 
challenged in the skin anaphylaxis model. IgE/Ag-activated MC provoked excessive 
edema in Serping1-/- animals (34.1 ± 6.1; p > 0.05 vs. WT; Figures 15E and 15F). As 
the mouse HAE model identifies allergen-sensitized MC as an initiator of pathological 
edema formation, the importance of this concept for the human disease state was 
further tested. In a survey, 38 well-characterized HAE patients from Switzerland were 
asked to report potential triggers of edema attacks. In 11 HAE patients, the onset of 
swelling was associated with allergic reactions to food and in 4 individuals edema 
formation was triggered by hyperimmune responses to insect toxins or drug allergens 
(Table 5).18 
 
 
 
Edema trigger Affected patients 
Food 11 
Insect sting 3 
Drug 1 
 
                                                      
18 This text section is taken from the publication Oschatz et al., 2011. 
Table 5. HAE patients were asked to self-report potential trigger factors for their swelling attacks. 
Identified allergens and affected cases in 38 patients. These data resulted from collaboration and were 
kindly provided by W. A. Wuillemin. 
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5.8 The murine model for hereditary angioedema type III 
To set up a mouse model for HAE III a double transgenic mouse (Albumin-tTAxHAE III 
mouse) using the tetracycline (Tet)-regulated expression system was generated. 
Expression of the gene of interest (factor 12 with the mutation 1032C→A) is shut down 
in the presence of Tet (“Tet-Off” System). Tetracycline controlled transactivator (tTA) is 
liver specific expressed under control of the albumin promoter in the Albumin-tTA 
transgenic mouse. The tTA stimulates the transcription of the gene of interest from a 
minimal promoter sequence (pminCMV) combined with Tet-response element (TRE) in the 
HAE III transgenic mouse (Figure 16).  
 
 
 
 
 
After oocytes injection of pTRE-Tight_FXIIThr328Lys 31 pups were born. Three of 
them carried the HAE III transgene. One HAE III transgenic male was breed with two 
female Albumin-tTA mice. Albumin-tTA mice were a kind gift from Dr. T.J. Liang from 
Figure 16. Liver specific inducible expression of Thr328Lys mutated human FXII by a Tet regulated
system. The albumin promoter restricts expression of the regulatory protein tTA to the liver. In the 
absence of Tet, tTA binds to TRE-sequence and activates the expression of Thr328Lys mutated human 
FXII protein.  
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the National Institutes of Health, Bethesda, Maryland, USA (Manickan et al., 2001). 
The two resulting litters contain 17 pups: 3/17 (18%) of the pups were HAE III 
transgenic, 2/17 (12%) were Albumin-tTA transgenic and 6/17 (35%) were double 
transgenic. 6/17 (35%) were males and 11/17 (65%) were females. Pups were 
phenotypically normal and fertile. For embryotransfer HAE III transgenic males were 
breed with C57BL/6 females. From the born pups 22/38 (58%) were HAE III transgenic. 
HAE III transgenic animals were mated with each other. The resulting litters were from 
normal size: 7-8 pups, which were phenotypically normal and fertile. Sex distribution 
was 45/106 (42%) male and 61/106 (58%) female. 95/106 (90%) of all pups were HAE 
III transgenic. Crossbreeding of embryotransfered HAE III transgenic mice with 
Albumin-tTA transgenic mice resulted in 62 pups. 25/62 (40%) of resulting pups were 
male and 37/62 (60%) were female. 1/62 (2%) mouse was HAE III transgenic, 40/62 
(65%) were Albumin-tTA transgenic and 18/62 (29%) were double transgenic. The 
Albumin-tTAxHAE III mouse should have a Tet-regulated liver specific expression of 
mutated human FXII. In the presence of Tet tTA cannot bind to the TRE-sequence and 
mutated human FXII is not expressed. If Tet is removed, then tTA binds to the TRE-
sequence and allows for the expression of the mutated human FXII (Figure 16, in our 
model, the Tet-derivative doxycycline instead of Tet is used and it is fed to the mice).  
The mouse model for HAE III will be used in future to address the function of 
Thr328Lys mutated FXII for vascular leakage and edema formation in vivo. Therefore it 
is planned to crossbreed F12-/- mice with Albumin-tTA and in following steps with HAE 
III mice according to the breeding scheme in Figure 17. The resulting animals will 
possess an inducible mutated human FXII expression on the background of 
heterozygote endogenous FXII level. This murine model mimics the situation in HAE 
type III patients and allows analyzing dose-dependent effects of mutated FXII in vivo. It 
is planned to provoke edema by increasing mutant FXII expression. 
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In summary, the data identify MC-heparin as an in vivo initiator of the proinflammatory 
contact activation system and demonstrate that heparin-driven BK formation, mediated 
by VASP, is an important component of MC-evoked vascular leakage. These findings 
suggest that heparin release may have broad clinical relevance in a variety of edema 
diseases associated with abnormal MC activation such as angioedema, urticaria or 
allergy.19 
                                                      
19 This text section is taken from the publication Oschatz et al., 2011. 
 
Figure 17. Generation of a mouse model for hereditary angioedema type III. F12-/- mice will be 
breed with Albumin-tTA mice expressing the tTA specifically in the liver. The pups will be heterozygous 
for F12 (F12+/-). A part of them will be Albumin-tTA transgenic. F12+/- Albumin-tTA transgenic mice will 
be mate resulting in animals, which are F12-/- Albumin-tTA transgenic. The animals will be breed with 
HAE III transgenic mice which have the TRE and are transgenic for the mutated FXII. All resulting pups 
will be F12+/-. Some of them will be double-transgenic for tTA and Thr328Lys mutated FXII. The 
Albumin-tTAxHAE III transgenic F12+/- mice will have a tetracycline-regulated liver-specific expression of 
the human mutated FXII. 
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6 DISCUSSION 
Increase in vascular permeability is characteristic for MC activity in allergic reactions 
and host defense is. It was suggested that MC histamine is the major mediator for 
leakage formation. Histamine receptor antagonists are used in therapy to treat edema 
formation associated with abnormal MC activity (Galli et al., 2008). BK, as well, is 
involved in increasing vascular permeability and is formed in allergic disease (Proud et 
al., 1983; Proud and Kaplan, 1988; Cicardi et al., 2010). MC-derived heparin, a highly 
sulfated polysaccharide, triggers BK formation via contact system activation in vitro 
(Hojima et al., 1984; Brunnee et al., 1997; Noga et al., 1999). Heparin has been used 
in clinic as an anticoagulant drug for over 75 years to prevent or treat thromboembolic 
disorders by prevention of blood clot generation (Jorpes, 1935; Li et al., 2009). This 
PhD thesis shows that MC-derived heparin has the ability to stimulate the contact 
system activation via FXII activation leading to BK generation in MC-mediated disease. 
 
Anaphylaxis results from the rapid degranulation of MC and can lead to death. 
Anaphylaxis can also be a side effect of heparin. Immediate hypersensitivity reactions 
of heparin are rare but can be life-threatening (Smith and Harkness, 2004; Blossom et 
al., 2008). Intravenous administration of heparin caused cutaneous necrosis in patients 
(Kelly et al., 1981). Or patient developed within minutes after subcutaneous heparin 
treatment tongue and lips swelling, hypotension, purities or cough (Odeh and Oliven, 
1992; MacLaughlin et al., 2002; Smith and Harkness, 2004). From November 2007 
through January 2008 hundreds of adverse reactions associated with heparin were 
observed in the United States and in Germany, and 159 deaths were reported to the 
Food and Drug Administration (Adam et al., 2010). Heparin produced in China and 
manufactured by Baxter Healthcare was identified to be the reason. Reported adverse 
patient reactions have included: stomach pain or discomfort, nausea, vomiting, 
diarrhea, decreased or low blood pressure, chest pain, fast heart rate, dizziness, 
fainting, unresponsiveness, shortness of breath, the feeling of a strong or rapid 
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heartbeat, drug ineffectiveness, burning sensation, redness or paleness of skin, 
abnormal sensation of the skin, mouth or lips, flushing, increased sweating, decreased 
skin sensitivity, headache, feeling unwell, restlessness, watery eyes, throat swelling, 
thirst, bleeding tendencies and difficulty opening the mouth 
(http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2008/ucm112384.htm, (Kishimoto et 
al., 2008)). Vials that caused reported reactions were analyzed with 1H nuclear 
magnetic resonance spectroscopy (NMR) and capillary electrophoresis. The 
contaminant was identified as an unusual oversulfated form of natural chondroitin 
sulfate A (Blossom et al., 2008; Guerrini et al., 2008; Luhn et al., 2010). In addition, 
dermatan sulfate, a known impurity of heparin, was also found in selected samples 
(Kishimoto et al., 2008). After realizing that the heparin was contaminated the quality 
and safety of pharmaceutical heparin had to be ensured, but both methods require 
expensive equipment and are time-consuming. Therefore new tests were developed: a 
fluorescence assay (Luhn et al., 2010), diffusion ordered spectroscopy (Bednarek et 
al., 2010) and weak anion exchange high-performance liquid chromatography (Hashii 
et al., 2010). But the HK cleavage assay (Figures 7, 8), could also serve as a simple 
bioassay or might complement the currently used NMR based analysis (Guerrini et al., 
2008) to screen for contaminants with high ability to activate the contact system.  
It was shown that oversulfated chondroitin sulfate (OSCS) activates the contact and the 
complement system: OSCS-contaminated heparin activates the kallikrein amidolytic 
activity in human plasma. Chondroitin sulfate A was also tested and failed to induce 
amidolytic activity. These data confirmed the results of Hojima (Hojima et al., 1984), 
who showed that OSCS but not Chondroitin sulfate A, B, C activate the kinin pathway 
(Kishimoto et al., 2008). FXII-dependence of contact system activation by the heparin 
contaminate was demonstrated by the use of FXII-depleted plasma: OSCS failed to 
induce kallikrein-activation. OSCS induced C5a production in a bell-shape dose-
dependent manner and in dependence of FXII. Pigs treated with OSCS-contaminated 
heparin showed hypotension (Kishimoto et al., 2008). While the group of Kishimoto 
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showed indirect evidence for the participation of BK in anaphylactic reaction caused by 
OSCS-contaminated heparin via amidolytic activity of kallikrein Adam and co-workers 
quantified directly the BK-release, induced by OSCS-contaminated heparin incubated 
with human plasma (Adam et al., 2010). In another study dextran sulfate was infused 
intravenously in miniature pigs, leading to profound and transient systemic arterial 
hypotension with concomitant reduction in kininogen. Dextran sulfate-induced 
hypotension was completely blocked by HOE-140 (Icatibant)-pretreatment. However 
kininogen was depleted, showing that hypotension is produced by kininogen cleavage 
and BK formation and mediated via kinin B2 receptor signaling (Siebeck et al., 1994). 
In this PhD thesis heparin instead of dextran sulfate was applied intra-arterially in rats 
leading to the same effects: rapid and pronounced blood pressure decrease (Figure 
10E). The procedure was repeated in mice, followed by a decrease of arterial blood 
pressure (Figure 10F). It was shown that this heparin-induced hypotonic effect was 
mediated via activation of the contact system since F12-/- and Bdkrb2-/- mice were 
almost protected. Using pharmacological substances to block FXII (PCK) and B2R 
(Icatibant) led to the same results. These data (Figures 10E-G) indicate the role of BK 
in immediate adverse reactions. 
Dextran sulfate is a synthetic negatively charged polysaccharide containing 4 sulfate 
residues per disaccharide in average. The same goes for OSCS (Guerrini et al., 2008). 
Heparin has 2.7 sulfate residues per disaccharide, while heparan sulfate contains only 
1 sulfate residues (Capila and Linhardt, 2002). The potency to activate FXII via contact 
decreased from dextran sulfate and OSCS to heparin. Heparan sulfate failed to 
activate the contact system (Hojima et al., 1984). The quantity of BK release in human 
plasma in presence of dextran sulfate was higher than that measured with heparin at 
the same concentration (Adam et al., 2010). This implicates that the negative charge 
density of polysaccharide is more important rather than the defined structure for 
contact activation triggering BK formation. This was demonstrated in Figures 8A-F. 
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Anaphylactoid reactions have been also reported in patients dialyzed with a negatively 
charged membrane and treated with an ACE inhibitor (Tielemans et al., 1990; Verresen 
et al., 1990). Aminopeptidase and carboxypeptidase N are degrading enzyme of BK, 
but ACE is the major one. ACE inhibitors lower ACE concentration with the result that 
patients develop more likely life-threatening edema (Summers et al., 2008).  
This PhD thesis demonstrates that IgE/Ag challenge led to MC degranulation with 
increased heparin activity in mice (triggering of HK cleavage Figure 10G and triggering 
of edema formation Figure 15). In KitW-sh/W-sh mice IgE/Ag challenge failed to increase 
vascular permeability, as shown before by Zhou et al. (Zhou et al., 2007) (Figure 15D). 
IgE/Ag-challenged mice had plasma that does not clot because of released heparin of 
>4 µg/mL. This concentration already induced BK formation (Figure 7). The animal 
model data are consistent with anaphylactic reactions in humans. Patients with 
anaphylaxis or anaphylactic shock due to insect bites show a significantly prolonged 
aPTT and an increased prothrombine time (Mazzi et al., 1994; Wang et al., 2005; 
Lombardini et al., 2009). The prolonged aPTT during anaphylaxis is caused due to 
activated MC, which release mediators such as heparin. The polysaccharide acts as an 
anticoagulant via binding to ATIII (Lombardini et al., 2009). 
 
The capacity of MC-heparin to activate FXII in plasma is controversial (Hojima et al., 
1984; Pixley et al., 1985a; Silverberg and Diehl, 1987; Pixley et al., 1991; Brunnee et 
al., 1997; Noga et al., 1999). Commercial heparin is purified from animal sources, 
usually bovine (in the past), porcine intestinal mucosa or lung by specific patented 
manufacturing processes. Since most heparins are obtained by different methods, the 
final products are specific in  their molecular and structural compositions and so they 
differ in their in vitro and in vivo properties, e.g. potency of contact system activation 
(Fareed et al., 2004). However, it seems, that heparin has 2 different functions for the 
FXII activation. First, heparin is a negatively charged polysaccharide, to which FXII 
binds to be autoactivated. Second, heparin increases the inhibition of FXII by ATIII. The 
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irreversible inhibitor binds to a pentasaccharide sequence of heparin with high affinity 
via an internal unique 3-O-sulfated glucosamine unit (Stead et al., 1976; Meyer et al., 
1981; Olson et al., 1993; Capila and Linhardt, 2002; Petitou et al., 2003). The dual 
function of heparin for contact system activation is indicated in a bell-shape dose 
response (Pixley et al., 1991; Jesty et al., 2005), which is also observed for OSCS 
(Kishimoto et al., 2008).  
 
Heparin in MC granules forms tight complexes with proteases (tryptases, chymases) 
and histamine. It is essential to obtain proper storage of tryptase (Hallgren et al., 2001). 
Upon MC activation the protease/heparin complexes are exocytosed (Stevens and 
Adachi, 2007). Still the association of heparin and protease is required for stabilization 
of tryptase (Addington and Johnson, 1996). The polysaccharide is also required for 
autocatalytic processing of protryptase to mature tryptase monomer (Hallgren et al., 
2000). To exclude that MC-derived heparin was still bound to tryptase or was 
contaminated heparin was purified as described.  
Evidence of the importance of heparin in packing of proteases in MC granules was 
adduced by the work of Humphries and Forsberg. Mice with targeted inactivation of the 
N-deacetylase/N-sulfotransferase-2 (NDST-2) gene are unable to synthesize sulfated 
heparin (Forsberg et al., 1999; Humphries et al., 1999) resulting in a largely decreased 
content of several MC proteases (tryptase, chymase) and histamine. NDST-2 deficient 
(NDST-2-/-) mice have fewer MC, with a reduced number of smaller granules and large 
empty vacuoles leading to reduced granula secretion after stimulation by IgE/Ag 
(Forsberg et al., 1999). These data suggest the physiological importance of heparin in 
MC granules for storage of other mediators and thereby for function of MC. 
The combined deficiency of histamine and several other MC mediators together with 
heparin (Forsberg et al., 1999) argue against the use of NDST-2-/- mice to specifically 
analyze the impact of activated MC triggered BK formation for endothelial barrier 
function. Reconstitution of MC deficient mice with NDST-2-/- MC led to a difficult 
reproducibility of IgE/Ag-induced edema formation. Therefore KitW-sh/w-sh mice were 
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employed, which are described as being MC deficient (Figures 11, 12, 15) 
(Grimbaldeston et al., 2005; Piliponsky et al., 2010). The IgE/Ag stimulated leakage 
formation in these animals was compared with WT and animals having deficiency in 
heparin-driven BK formation (F12-/- mice) and Bdkrb2-/- mice (that are resistant to BK 
signaling but susceptible for histamine mediated leakage) to specifically address the 
importance of activated MC triggered BK formation for vascular permeability. 
 
Humans with decreased level or functional defect of C1INH have HAE type I or II, 
whereas HAE type III is associated with a single point mutation in factor 12 gene 
(Cichon et al., 2006). HAE is characterized by recurrent attacks of angioedema and BK 
is the key mediator of symptoms (Nussberger et al., 2002; Cicardi et al., 2010). But the 
swellings are not associated with an increased pro-thrombotic risk (Nzeako et al., 
2001). This supports the concept of selective activation mechanisms for individual 
contact-system initiated pathways. Patients (Nussberger et al., 1998; Zuraw, 2008) and 
the Serping1-/- mice (Figure 11, 12E) have normal vascular permeability under non-
stimulated conditions. This is in contrast with C1INH deficient mice, generated by Han, 
which have aconstantly increased vascular permeability under non-stimulated 
conditions (Han et al., 2002). The different phenotypes of the two mouse models can 
be caused by different technologies used to inactivate the Serping1 gene. The 
Serping1-/- mice were generated via random mutagenesis, which deleted exon 2, 
resulting in complete termination of C1INH protein synthesis (Figure 4). In contrast Han 
and coworkers used a random insertional mutagenesis technique (gene trap), in which 
the trapping vector is inserted into a splice-acceptor site in intron 6 (210 bp 5´of exon 
7). Therefore Serping1 gene expression is not complete, but the C1INH protein is 
truncated (composed of exons 1-6, amino acids 1-347 of 504 in the mature protein, 
accession no. AAC40149) and fused to trap-vector, which codes β-galactosidase 
(Ullrich and Schuh, 2009). The truncated C1INH lacks the active site (encoded by exon 
8), which includes the signal peptide in WT C1INH. Therefore the mutant could be 
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secreted into the plasma. In any case, it affects the permeability leading to increased 
basal permeability. So the biological function and location has to be determined. In 
Western Blot analyses Han showed only the full-length C1INH protein proving the 
deficiency of C1INH. But he forgot to show the size in which the truncated variant is 
supposed to be. 
While the Serping1-/- mice is a model for HAE II, the double transgenic mouse 
(Albumin-tTAxHAE III mouse) line, described in this PhD thesis, is a model for HAE III. 
Analyses of the double transgenic mice need to be done to show that the mouse line 
exhibits the conditional expression of 1032C→A point mutated human FXII in the liver. 
Expression of mutated FXII could be tested via Western blotting of plasma samples or 
digested liver-tissue of Albumin-tTAxHAE III mice with the α-FXIIHAE antibody, which 
exists in the laboratory group. Additional it has to be demonstrated, that the expression 
of the HAE III transgene could be completely suppressed by Tet administration and 
that such a suppression could be reversed upon discontinuation of Tet. The biological 
significance of this system has to be confirmed by phenotypic studies, in which the 
double transgenic animals develop angioedema triggered by to investigative stimuli in 
the absence of Tet. 
Several transgenic mouse models have been developed using the Tet-regulated 
system in various target tissues or organs: in lymphoid cells, cardiac muscles and rat 
liver (Gossen and Bujard, 1992; Passman and Fishman, 1994; Manickan et al., 2001). 
For the HAE III model it was reasonable to adopt a liver specific expressed tTA under 
control of the albumin promotor, because both, albumin and FXII are produced in the 
liver. Therefore the human mutated FXII, which could be inserted in the DNA of all 
body cells, is only expressed in the liver, where the tTA is synthesized in the absence 
of Tet. A Tet-Off system was applied instead of mutation techniques in factor 12 gene, 
because the Tet -regulated system allows analyzing not only for a switch on-switch off 
expression, but also for a dose-dependent effect of mutated FXII in vivo. 
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Following contact-induced activation, FXIIa initiates several protease cascades in 
plasma: the complement and fibrinolytic system, kallikrein-kinin system and the intrinsic 
pathway of coagulation (Muller and Renne, 2008; Oschatz et al., 2011). Using 
genetically modified mice, it was shown that FXIIa-initiated fibrin formation is essential 
for arterial thrombus formation (Renne et al., 2005a) and ischemia reperfusion injury in 
an experimental model of stroke (Kleinschnitz et al., 2006). Polyphosphates secreted 
by platelets activate FXII. FXIIa activates, via its substrate FXI, the intrinsic pathway of 
coagulation and, via PK, the kallikrein-kinin system. Heparin, in contrast, leads only to 
FXII-mediated BK formation without FXI-triggered coagulation (Figure 7D). These data 
confirm the results of Kelly et al., where i.v. administration of porcine heparin leads to 
necrosis but histologically not to fibrin thrombi in capillaries and vessels (Kelly et al., 
1981). The in vivo relevance of other FXIIa triggered pathways is less clear. In vitro, 
FXIIa initiates the classical complement system pathway that culminates in the 
generation of C3a and C5a (Ghebrehiwet et al., 1981). Both mediators contribute to 
anaphylactic reactions (del Balzo et al., 1989) and are thought to play a role in adverse 
reactions induced by contaminated heparin (Schwartz, 2008). Since B2R antagonists in 
rodents and genetic ablation of BK receptors in mice almost completely abolished 
heparin-induced adverse effects in our animal models (Figure 10E, 10F, 11, 12C and 
13), FXIIa-triggered hypotension and  anaphylaxis appear to be predominantly BK 
mediated. In a swine model, a dextran sulfate infusion-induced transient systemic 
hypotension that was completely blocked by the B2R antagonist Icatibant (Siebeck et 
al., 1994).  
MC heparin, highly sulfated polysaccharides and polyphosphates are not the only in 
vivo activators of the FXII/PK-system. Recently, misfolded proteins were identified as a 
FXII activating surface in humans (Maas et al., 2008). Similar to heparin or dextran 
sulfate (Johne et al., 2006), the binding of FXII to protein aggregates specifically trigger 
the kallikrein-kinin pathway without activating the FXIIa substrate, FXI (Maas et al., 
2008), which drives the intrinsic clotting pathway. In contrast, extracellular RNA 
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activates FXII, and a synthetic RNA analog is a procoagulant (Kannemeier et al., 
2007). Since FXI and PK have homologous structures, and are both complexed with 
HK to the cell surface in plasma (Renne et al., 2002), the detailed mechanism for 
selective activation of FXIIa substrate PK over FXI is not completely understood but 
could be caused because of a higher plasma concentration of PK vs. FXI, different 
FXII-activation mechanisms and different FXIIa-forms (Schmaier, 2008; Renne, 2012). 
 
In conclusion, this PhD thesis offers arguments for the immediate adverse heparin 
effects and for the 90-year-known phenomenon, that MC-driven anaphylaxis is 
associated with impaired plasma clotting (Bulger, 1918): that now can be explained by 
negatively charged MC heparin. The polysaccharide activates FXII-dependent the 
plasma contact system leading to BK formation with pathological MC-mediated 
inflammation, hypotension and edema formation.  
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7 CONCLUDING REMARKS  
MC have a central function in allergic and inflammatory diseases and contribute to 
increased vascular permeability, allergic and anaphylactic reactions. Upon activation 
MC release a wide range of mediators. One of them is heparin, which is commonly 
used as an anticoagulant drug. 
This study identifies a mechanism, by which MC-heparin increases vascular 
permeability. The negatively charged polysaccharide initiates FXII-driven contact 
activation. FXII triggers the kallikrein-kinin system leading to BK formation. The 
inflammatory mediator induces swellings, anaphylactic and inflammatory symptoms, 
which are known to be associated with aberrant MC activity. Thus, the study provides a 
novel link between MC-driven pro-inflammatory reactions and the kallikrein-kinin 
system (Figure 18). Drugs that block BK or FXII activity protect from adverse MC-
driven effects in patients and genetically engineered mouse models and could be a 
new strategy to treat MC-driven allergic diseases.         
  
 
 
 
.
Figure 18. Mast cell-released heparin increases vascular permeability in vivo: a novel link 
between mast cell-mediated diseases and the kallikrein-kinin system. This figure has been published 
before - online as a graphical abstract to (Oschatz et al., 2011). 
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α                               
µ                               
µg   
µL   
µm                            
µM                            
ACE                          
Ag                             
aPTT                        
ATIII                         
BK                            
bp                             
B2R                          
BSA         
bw                
C1INH                      
C48/80                     
Da                            
dNTP                        
ELISA                       
FITC                         
FX                            
FXa                          
FXI  
FXII  
FXIIa                        
g  
g                               
h                               
HAE                          
HK 
IgE                            
IgG                           
ITAM                        
anti 
micro 
microgram 
microliter 
micrometer 
micromolar 
angiotensin-converting enzyme 
antigen 
activated partial thromboplastin time 
antithrombin III 
bradykinin 
base-pair  
kinin B2 receptor 
bovine serum albumin 
bodyweight 
C1 esterase inhibitor 
compound 48/80 
Dalton 
deoxyribonucleotide 
enzyme linked immunosorbentassay 
Fluorescein isothiocyanate 
plasma coagulation factor X 
activated plasma coagulation factor X 
plasma coagulation factor XI 
plasma coagulation factor XII 
activated plasma coagulation factor XII 
gram 
gravity 
hours 
Hereditary angioedema 
high molecular weight-kininogen 
immunoglobulin E 
immunoglobulin G 
immunoreceptor tyrosine–based activation motifs 
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i.p.                            
i.v.                            
k  
L                               
LK                             
M  
mA                            
mAb                          
MC                           
mg                            
min                           
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mm                           
mM  
mmHg                
MW                           
ng                             
nm  
nM  
NO                            
NP                            
pAb                           
PAGE  
PCK 
PCR                         
pH  
PK                            
PKA                          
PKC                          
PKG                         
PPK                          
PPP                          
OD600                        
OSCS                       
rpm   
RT                            
SEM                         
intraperitoneal 
intravenous 
kilo 
liter 
w molecular weight-kininogen 
Molarity (mol/L) 
miliampere 
monoclonal antibodies 
mast cells 
miligramm 
minutes 
mililiter 
millimeter 
millimolar 
millimeter of mercury 
molecular weight 
nanogramm 
nanometer 
nanomolar 
nitric oxide 
normal plasma 
polyclonal antibodies 
polyacrylamide gel 
H-D-Pro-Phe-Arg-chloromethylketone 
polymerase chain reaction 
negative base-10 proton concentration 
plasmakallikrein 
cyclic adenosine monophosphate-dependent protein kinase 
protein kinas C 
cyclic guanosine monophosphate-dependent protein kinase 
plasma prekallikrein 
platelet pure plasma 
optical density at a wavelength of 600 nm 
over-sulfated chondroitin sulfate 
revolutions per minute 
room temperature 
standard error of the mean 
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SDS  
sec                           
Tet                            
tetR                          
TRE                          
tTA                           
U  
UV                           
V  
VASP                       
vs.                            
w/o  
WT                           
 
standard deviation 
sodium dodecyl sulfate 
seconds 
tetracycline 
tet repressor protein 
tetracycline-response element 
tetracycline transactivaor 
unit 
Ultraviolet 
Volt 
vasodilator-stimulated phosphoprotein 
versus 
without 
wild-type 
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